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ABSTRACT 
A liquid phase microextraction based on single hollow fibre followed by liquid 
chromatographic determination was developed for the extraction and 
quantification of the hallucinogenic muscimol and its two precursors, tryptophan 
and tryptamine from urine samples. A multivariate design of experiment was used 
in which a half fractional factorial approach was applied to screen six potential 
factors (donor phase pH, acceptor phase concentration, supported liquid 
membrane composition, stirring rate, extraction time and salt content) for their 
extent of vitality on the extraction of muscimol, tryptophan and tryptamine using 
the developed method. Four factors were identified as essential for an enhanced 
enrichment of each of the three research analytes from diluted urine samples.  
The paired vital factors were then optimized using central composite designs 
where empirical quadratic response models were used to visualize the response 
surface through contour plots, surface plots and optimization plots of response 
output. When the muscimol-based optimum factor levels were applied for the 
simultaneous extraction of the three research analytes, a composite desirability of 
0.687 was obtained implying that the set conditions were ideal for a combined 
extraction of the analytes from the donor phase into the acceptor phase across a 
supported liquid membrane impregnated with a carrier molecule. This was an 
acceptable result considering that only the optimized muscimol factor levels were 
set as universal factor values.  Muscimol was the analyte of interest in this 
research. 
The composite desirability value was predicted by setting the extraction 
conditions to 20% (w/w) di-(2-ethylhexyl) phosphoric acid (DEHPA) in dihexyl 
ether (DHE) supported on the walls of a hollow fibre into a 200 mM HCl acceptor 
phase inside the hollow fibre from a 20% (v/v) diluted urine donor phase spiked in 
the 0.1 – 10 µg mL-1 analyte concentration range maintained at pH 4 and stirred at 
800 rpm for 60 mins.  Experimentally, average enrichments of 4.1, 19.7 and 24.1 
were obtained for muscimol, tryptophan and tryptamine, respectively. 
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The complexity of urine and the anionic nature of the carrier molecule embedded 
on the supported liquid membrane resulted in interfering peaks that could not be 
completely resolved from the analyte peaks. Thus matrix-based calibration curves 
were used to address matrix effects.  
Various statistical approaches were used to validate suitability of the developed 
method for its potential use in quantifying muscimol and its precursors from urine 
samples. These validation measures were used as a way of determining the 
method’s ability to maintain the extraction process at equilibrium over a specific 
range of analyte concentrations over a period of analyte existence in a urine 
sample. The r² values of the matrix-based linear regression prediction models 
ranged from 0.9933 to 0.9986. The linearity of the regression line of the matrix-
based calibration for each analyte was directly linked to the analyte enrichment 
repeatability. Simultaneous analyte enrichment repeatability over a 0.1 – 10 µg 
mL
-1
 analyte spiking concentration ranged from an RSD value of 8.3% to 13.1%. 
Limits of detection were 0.021 µg mLˉ¹, 0.061 µg mL-1 and 0.005 µg mL-1 for 
muscimol, tryptophan and tryptamine, respectively.    
Other validation parameters that were considered included specificity (and 
selectivity), accuracy, robustness, extraction range and system suitability. The 
accuracy of the developed method was reported as the reproducibility of 
enrichment factor values over six spiking concentrations used in constructing 
matrix-based calibration curves. System suitability was limited to an HPLC-UV 
approach. Method suitability was addressed through a comparative summary in 
which the LOD, LOQ and r² values for the developed method were compared to 
other methods that have been used to extract muscimol from urine samples. The 
relevance or acceptability of the enrichment factor values obtained for the 
extraction of the three analytes was achieved by comparison with enrichment 
factor values of several compounds with similar polarity that have been extracted 
from urine samples using carrier-mediated hollow fibre liquid phase 
microextraction. 
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1 INTRODUCTION         
Hallucinogenic compounds are of particular interest because of their documented 
pharmacokinetics and physiological effects if consumed at elevated levels. 
Literature reports and anecdotal evidence on the continued intentional 
consumption of hallucinogenic mushrooms for their mind enhancing effect and 
the accidental poisoning is a cause for concern (Tsujikawa et al., 2007; van 
Amsterdam et al., 2011). It is therefore necessary to analyse body fluids from 
individuals suspected to be under the influence of hallucinogens so as to 
prospectively curb the possibility of unsocial behaviour and where possible break 
causalities. Such results can be used as legal evidence in forensics and in food 
toxicology.  
Development of analytical methods for quantification of hallucinogenic 
compounds in urine samples of individuals suspected to have consumed 
hallucinogenic mushrooms whether intentionally or by mistake is essential in 
toxicology and criminology. The reliability of results for legal investigation of 
culprits or victims depends solely on the validity and the accuracy of the method 
used for quantification. Muscimol (MUS) is a hallucinogenic compound found in 
Amanita mushrooms and its quantification in urine can be used to prove prior 
exposure to Amanita mushrooms. It is excreted unchanged in urine. Very few 
publications have been reported for quantifying MUS in human body fluids. Solid 
phase extraction has been reported by Hasegawa et al. (2013) to extract MUS 
from blood serum (Hasegawa et al., 2013). NMR-NOESY spectroscopy, capillary 
electrophoresis coupled with electrospray tandem mass spectrometry and cation 
exchanger with GC-MS with derivatization have also been reported (Deja et al., 
2014; Ginterová et al., 2014; Stříbrný et al., 2012). 
Sample preparation is still seen as crucial and critical in any analytical 
determination and can be viewed as ‘rate determining’ in any analytical procedure 
(Abadi et al., 2012; Chimuka et al., 2011). Currently simple, cheap and 
environmental friendly sample preparation techniques especially those based on 
liquid phase microextractions (LPME) are favoured in which sampling, 
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extraction, and enrichment concentration are all integrated into a single extraction 
unit (Lin et al., 2013; Pena-Pereira et al., 2010a, 2010b). 
Since the publication of the first paper on liquid phase microextraction (LPME) 
in1996, different approaches have been developed as an attempt to improve 
recoveries, facilitate automation and miniaturize organic solvents used. One of 
these techniques is single hollow fibre liquid phase microextraction (HF-LPME) 
(Chimuka et al., 2011; Dadfarnia and Shabani, 2010; Dziarkowska et al., 2008; 
Lin and Chen, 2006; Pena-Pereira et al., 2010a, 2010b; Poliwoda et al., 2010). 
HF-LPME was first introduced by Pedersen-Bjergaard and Rasmussen in 1999 as 
a viable fabrication to conventional flat fiber membrane sample preparation 
modules for chromatographic and electrophoretic analysis of trace amounts of 
ionizable analytes (Abadi et al., 2012; Al Azzam et al., 2010; Lee et al., 2008; 
Pena-Pereira et al., 2010a). Other LPME techniques include single drop 
microextraction  introduced by Liu and Dasgupta and dispersive liquid–liquid 
microextraction designed to eliminate use of the micro-syringe (Asensio-Ramos et 
al., 2011; Lin et al., 2013). 
The HF-LPME technique is based on compound dissolution from a small volume 
of aqueous sample solution, the donor phase (DP) into a supported liquid 
membrane (SLM), usually a low polarity organic solvent that is impregnated in 
the pores of a hydrophobic porous hollow fibre (HF).The analyte is then back 
extracted into a micro-volume acceptor phase (AP) placed inside the lumen of the 
fiber through ionization and diffusion processes (Chimuka et al., 2011, 2010; 
Ebrahimpour et al., 2011a). For very polar analytes or analytes that exist in their 
charged state in the entire pH working range, a carrier molecule can be 
impregnated into the SLM to aid transfer (Asensio-Ramos et al., 2011; Chimuka 
et al., 2011; Ebrahimpour et al., 2011a).  
The AP now containing the analyte is directly injected into the analytical 
instruments for identification and quantification (Asensio-Ramos et al., 2011). 
Reverse phase columns tend to fail in separation of polar compounds leading to 
the advent of hydrophilic interaction liquid chromatography (HILIC) columns. 
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HILIC columns continue to find application in extraction and separation of polar 
analytes from complex biological samples. 
A robust experimental design is one that considers interdependence of design 
elements and provides a full insight of interaction between the factors that affect 
the response output most. Multivariate experimental approaches allow designers 
to target those factors that are more important than others. The most common 
factor screening design in experimental research is the factorial approach where 
there are multiple factors and the researcher is interested in the combined effect on 
the response output and the need to simultaneously investigate them. The 
objective of these designs is to identify factors that have a significant effect on the 
response among factors that have been predicted to have an impact on an 
experimental response. Once the power factors have been identified, their 
interrelationships that maximize the response output are predicted using response 
surface designs. The two common approaches in response surface designs are the 
central composite design (CCD) and the Box-Behnken design (Atkinson et al., 
2007; Cox and Reid, 2000).  Where a simultaneous extraction and quantification 
of several analytes is needed, a desirability function is used to measure how the 
universal factor values satisfy the targeted response output of a design.  
As far as this research is concerned, nothing has been published on extraction of 
muscimol and ibotenic acid or psilocin and psilocybin using HF-LPME. The 
present work targeted extraction of muscimol and its two precursors, tryptophan 
(TRP) and tryptamine (TA) using HF-LPME in conjunction with HPLC-UV 
technique. This technique is attractive because unlike solid phase extraction, it is 
simple, environmentally friendly and inexpensive. It does not require a further 
clean-up or preconcentration step. HF-LPME technique can also be selective if all 
the critical parameters for an effective HF-LPME extraction are carefully 
optimised. Multivariate approaches to experimental design are a solution in this 
regard.  
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2 LITERATURE REVIEW 
 Hallucinogenic compounds 2.1
 Definition 2.1.1
A hallucinogen is a pharmacologically psychoactive agent that alters the state of 
the mind by either enhancing one’s consciousness, perception, emotion and 
thought or inducing new non-ordinary psychological experiences that lead to an 
exaggerated freedom of thought (Nichols, 2004). The experience may be pleasant 
and stimulating as exemplified in euphoria and activated sensory awareness, or 
hypnagogic and depressant. This reinforcing effect of psychoactive substances has 
been utilized for illicit recreational purposes, to purposefully augment one's 
consciousness, or as entheogens (Hasler et al., 2004). Either case, individuals tend 
to use them excessively in order to attain the climax of the feeling despite 
negative consequences. The top culprits are the youth that have a natural 
adventurous behaviour that draws them to pryingly venture into the unexpected 
and at times risky life experiences that involve experimenting with illicit 
hallucinogenic drugs (Tsujikawa et al., 2007; van Amsterdam et al., 2011).   
A hallucinogen can be psychedelic, dissociative or deliriant depending on its 
subjective and behavioural effects. A psychedelic hallucinogen falsifies cognitive 
and perceptual aspects of the mind by provoking hidden but real aspects of the 
mind. It alters the brain’s ability to filter certain sensory transmissions associated 
with perceptions and emotions from reaching the conscious mind. A psychedelic 
experience is often ecstatic followed by extra-ordinarily paresthetic feelings 
characterized by tremendous sensations like trance, euphoria and synaesthesia. 
However at elevated levels the sensations and feelings may result in panic attacks 
due to fear of losing control, paranoia and mania which may result in reckless 
and/or dangerous behaviour with the situation elevated for schizophrenics and 
other drug abusers. Examples include lysergic acid diethylamide (LSD), 
psilocybin and psilocin, methylenedioxymethamphetamine, mescaline and N,N-
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dimethyltryptamine (Hasler et al., 2002; Nichols, 2004; Passie et al., 2002a; 
Wittmann et al., 2007). 
Dissociatives result in depersonalization and derealization experiences where 
one’s feelings become detached from the body and his surrounding, and the world 
becomes dream-like. The individual may either experience catalepsy or seize to 
actively take control of his actions and yet goes through them or has improper 
judgment of his mobility, a condition known as dysmetria.  Deliriants induce 
symptoms similar to delirium, an acute confusional syndrome characterised by 
general instability, dysmetria and even severe disorientation, with potential 
aggressive behaviour. The neuropsychiatric experience due to muscimol and 
ibotenic acid is considered sedately hypnotic, depressant, dissociative and 
deliriant (Becker et al., 1999; Michelot and Melendez-Howell, 2003; Tsujikawa et 
al., 2007). The physical chronosymptomatology hallucinogenic influence includes 
vomiting, dryness of the lips and mydriasis (Michelot and Melendez-Howell, 
2003). 
Almost all hallucinogens contain nitrogen and are therefore classified as alkaloids 
with the exception of Tetrahydrocannabinol and salvinorin A. Psilocybin and 
psilocin are indolealkyltryptamine derivatives while ibotenic acid and muscimol 
are isoxazole alkaloids (Chen et al., 2011; Hasler et al., 2004; Manevski et al., 
2010). 
 Mushrooms: history, uses and abuses 2.1.2
A mushroom (or toadstool) is a fleshy, macroscopic spore-bearing fruiting fungal 
body that can either be hypogeous, epigeous or paratrophic (Miles and Chang, 
2004). They belong to the Basidiocota phylum and fall under Agaricomycetes that 
are characterized by basidia on filamentous gills. The basidia are sexual structures 
that produce reproductive basidiospores. Typical mushrooms are of the order 
Agaricales. Mushrooms in the Amanita genus such as Amanita muscaria (Figure 
1a), Amanita pantheria and Amanita ibotengusske, and Psilocybe genus like 
Psilocybe cubensis (Figure 1b) and Psilocybe semilanceata are known to have 
hallucinogenic properties while the Agaricus genus is considered edible. The 
Amanita mushrooms contain mainly muscimol, ibotenic acid, muscazone, and 
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muscarine. Muscimol is considered the principal psychoactive agent (Gennaro et 
al., 1997; Hasler et al., 2004, 2002; Michelot and Melendez-Howell, 2003). 
Hallucinogenic effects of Psilocybe mushrooms are mainly due to psychedelics 
psilocybin and psilocin with psilocin as the pharmacologically active agent.  
Agaricus bisporus (Figure 1d) is commercially cultivated, harvested and marketed 
as the white button mushroom in popular supermarkets in South Africa and the 
world. The first mushroom to be intentionally cultivated for its delicacy was the 
paratrophic Auricularia auricular (Figure 1c) which is traced back to around 1400 
years ago (about A.D 600) in China while Agaricus bisporus was first cultivated 
by the French in about the year 1600 (Miles and Chang, 2004).  Most mushrooms 
are conditionally cosmedible in that the toxins are either leached out or destroyed 
by moderate heat when cooking (Rubel and Arora, 2008).      
  
Figure 1  The hypnagogic Amanita muscaria (a), the psychedelic Psilocybe 
cubensis (b), the first ever cultivated paratrophic Auricularia auricular (c) and 
Agaricus bisporus at the shelves of a common supermarket in SA (d) 
 Pharmacokinetics and physiological effects of psilocin and muscimol 2.1.3
Psilocybin (O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine) and psilocin (4-
hydroxy-N,N-dimethyltryptamine) first isolated from Psilocybe mexicana by 
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Hoffman in 1957  are indolealkyltryptamine derivative and have a structural 
similarity to the excitatory neurotransmitter, serotonin (Figure 2) (Chen et al., 
2011; Geyer and Vollenweider, 2008; Hasler et al., 2004; Kamata et al., 2010; 
Lindenblatt et al., 1998; Manevski et al., 2010; Nichols, 2004; Passie et al., 
2002b). They act as serotonergic agonists at the serotonin receptors in the brain. 
Pharmacokinetically, psilocybin is a pro-drug that undergoes first pass 
metabolism in the liver into the pharmacologically active compound, psilocin by a 
dephosphorylation reaction in the presence of alkaline phosphatases (Anastos et 
al., 2006; Hasler et al., 2004, 2002; Passie et al., 2002b). Psilocin is then either 
glucuronated to be excreted in the urine, or further converted to other non-
exhilarating metabolites that enter the systemic circulation. (Hasler et al., 2004, 
2002; Manevski et al., 2010) 
 
Figure 2  Psychedelics: psilocybin (a) and psilocin (b), and the neurotransmitter, 
serotonin (c) 
Muscimol (5-(Aminomethyl)-isoxazol-3-ol) is an isoxazole alkaloid and has a 
structural similarity to the sensory inhibitory γ-aminobutyric acid (GABA) 
neurotransmitter (Figure 3). Produced naturally in the Amanita species, muscimol 
is also a decarboxylation product of ibotenic acid. Ibotenic acid is a glutamate 
neurotransmitter receptor agonist. Muscimol and ibotenic acid were discovered in 
1964 from the fly-agaric mushrooms (Michelot and Melendez-Howell, 2003; 
Rogers, 2011). 
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Figure 3 Psycho-sedatives: ibotenic acid (a) and muscimol (b), and gamma-
aminobutanoic acid (GABA), the neurotransmitter (c)  
The mushrooms can be ingested as fresh or dried fruit bodies, in a tisane or 
combined with other foods to mask the bitter taste. For example in the 
Netherlands Psilocybe cubensis is ground and put as ingredients of chocolate bars 
while some users have injected mushroom extracts intravenously (van Amsterdam 
et al., 2011). Some poisoning is accidental in which the poisonous mushrooms are 
mistaken for edible ones (Tsujikawa et al., 2007). The pharmacokinetics and 
physiological effects of psilocin and muscimol are summarized in Table 1 (Becker 
et al., 1999; Berge, 1999; Hasler et al., 2004; Michelot and Melendez-Howell, 
2003; Passie et al., 2002b; Tsujikawa et al., 2007; van Amsterdam et al., 2011). 
The intensity and duration of the effects depend on species, dosage, brain 
chemistry, individual physiology, and whether the culprit is using other drugs 
(Becker et al., 1999; Berge, 1999; Passie et al., 2002b; van Amsterdam et al., 
2011). The 4 – 10 mg dosage that induces psychedelic effects corresponds to 
about 50–300 µg kgˉ¹ of body weight. A 10 mg dosage corresponds roughly to at 
least 1 g of dried magic mushrooms with 1 %w/w hallucinogen content. However 
the accuracy of an effective dosage remains unresolved due to the potency 
variation factors discussed above and the presence of other active psychedelics 
like phenylethylamines in magic mushrooms.  
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Table 1 Pharmacokinetics and physiological effects of psilocin and muscimol  
 Psilocin Muscimol 
Action Agonist at serotonin  
neurotransmission receptors 
Agonist at GABA 
neurotransmission receptors 
Effect Psychedelic: paresthetic 
feelings characterized by 
tremendous sensations like 
trance, euphoria and synesthesia 
dissociative and deliriant: 
Depersonalization, 
derealization, sedately 
soporific, hypnagogic 
depressant 
Onset 10 – 40 mins and lasts up to 8 h 2 – 3 h and lasts up to 8 h 
Minimal dosage 4 – 10 mg 10 – 15 mg 
Excretion In urine as psilocin O-
glucoronide 
Excreted unchanged in urine 
Toxicity LD50 of 280 mg kgˉ¹   in rats LD50 of 45 mg kgˉ¹   in rats 
 
Even though the hallucinogenic effect has minimal intellectual impairment, low 
toxicity with LD50 of 280 mg kg
-1
  for psilocybin which is equivalent to about 17 
kg of fresh mushrooms to be consumed to reach this rate in humans (Gable, 2004; 
Passie et al., 2002b; van Amsterdam et al., 2011) and absence of addiction 
(Nichols, 2004; Passie et al., 2002b), several case studies have declared that under 
elevated levels of psychoactive agents in the body, the individual becomes a risk 
to himself and his surroundings characterised by potentially fatal accidents, self-
injury, and suicide attempts (Nichols, 2004; Sticht and Käferstein, 2000; van 
Amsterdam et al., 2011). The elevated sensations may result in reckless and/or 
dangerous behaviour with the situation elevated for schizophrenics and other drug 
abusers (Hasler et al., 2002; Nichols, 2004; Passie et al., 2002b; Wittmann et al., 
2007). The tenacity of the hallucinogenic effect becomes detrimental especially to 
those with other ailments, driving, operating machines or walking the busy streets 
and roads. It is therefore essential to analyse body fluids from individuals 
suspected to be under the influence of hallucinogens so as to prospectively curb 
the possibility of unsocial behaviour. With reports of mushroom abuse and 
10 
 
casualties continuing to be published (Asselborn et al., 2000; Becker et al., 1999; 
Berge, 1999; Chen et al., 2011; Sticht and Käferstein, 2000; van Amsterdam et al., 
2011), it is essential to scientifically evaluate and understand the recreational 
usage of hallucinogenic mushrooms. This starts with development of viable 
quantification methods. 
 Hallucinogenic research: the past, the present and the future 2.1.4
Although the use of hallucinogenic mushrooms especially for shamanic and 
consumption purposes is traced back to historic times as evidenced in rock art and 
ancient documents belonging to primitive societies like the soma of ancient India 
scientific studies only started in the early 20th century. The most ancient portrait 
of mushrooms on a rock is found in the desert town of Tassil in Algeria 
discovered by Samorini in 1992 dating back to about 7 000 – 9000 B.P that 
Guzman et al. 1998 predicts to be Psilocybe mairei (Akers et al., 2011; Gennaro 
et al., 1997; Guzmán et al., 1998; Nichols, 2004). However, Mexico (mainly 
Psilocybe species discovered by Heim in 1956) and Siberia (mainly Amanita 
muscaria) have been identified as the two major countries with the most 
documented historic shamanistic usage of mushrooms (Akers et al., 2011; 
Gennaro et al., 1997; Guzmán et al., 1998). The first publication on psychoactive 
plants was Louis Lewin’s Phantastica in 1928 which was meant to describe the 
sensations associated with these mushrooms (Nichols, 2004). More research 
intensified with Weitlamer rediscovering the Mexican hallucinogenic mushrooms 
in 1936 while Albert Hoffman’s discovery of the semi-synthetic LSD in 1938 is 
arguably responsible for the explosion of interest in the study of hallucinogens 
(Berge, 1999; Geyer and Vollenweider, 2008; Vollenweider et al., 1998). It was 
during this time that ethno-mycological explorations exploded provoking a 
hallucinogen naming frenzy as an attempt to describe the totality of the feeling. 
Psychedelic, psychotomimetic, psychogenic, schizophrenic, mysticomimetic and 
entheogenic were some of the terms proposed. Psychedelic was coined by 
Humphrey Osmond to describe the mysterious mind manifesting extent while 
Ruck C. A.  proposed entheogen to describe spiritual enhancing abilities during 
religious rituals (Nichols, 2004; Ruck et al., 1979). 
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 However experiments were prohibited in the late 1960s. Despite prohibition, the 
recreational, spiritual, and medical use of psychedelics continued illegally and still 
continues today. In October 27, 1970 both psilocybin and psilocin were officially 
labelled as hallucinogens and eventually classified under Schedule 1 drugs 
(Nichols, 2004). Schedule 1 drugs are illicit, high potential for abuse compounds 
with no known medical benefit and a lack of accepted safety. However the 
psychedelic-containing mushrooms were not included. Thus the techniques of 
growing psilocybin mushrooms continued to be published in several books, like 
the Psilocybin: Magic Mushroom Grower's Guide of 1981, with the end of the 
20th century seeing the mushrooming in production of psilocybin as an entheogen 
of choice.  
The turn of the century has seen some organizations like the Heffter Research 
Institute and Center for Cognitive Liberty and Ethics, and proponents including 
Albert Hoffman calling for legalizing research into the safety and efficacy of 
hallucinogens.  Thus during the last decade there has been a resurgence of 
authorized interest in hallucinogen therapeutic and recreational applications 
(Johnson et al., 2008; Nichols, 2004). With loopholes in legislation leading to 
legal availability of the magic mushrooms in smart shops and online in European 
countries (Chen et al., 2011; Hasler et al., 2002; Tsujikawa et al., 2007; van 
Amsterdam et al., 2011), there was a need to reconsider a broader and prospective 
approach through legalized scientific research. Many western countries have now 
started to legally approve studies to test the physiological effects and therapeutic 
possibilities of hallucinogens. In 2008, Johnson and colleagues together with the 
Johns Hopkins research team published guidelines and recommendations for 
screening potential study volunteers when performing hallucinogen clinical trials 
in humans (Johnson et al., 2008). 
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 HF-LPME sample preparation      2.2
 Principle of the HF-LPME 2.2.1
The HF-LPME technique involves transfer of an analyte from a DP where it exists 
in its neutral form across a liquid membrane on the pores of a hollow fibre 
(HF).The analyte is accepted by a phase placed inside the lumen of the fiber 
through ionization and diffusion processes (Chimuka et al., 2011, 2010; 
Ebrahimpour et al., 2011b). The HF-LPME technique can be classified as either a 
two-phase or three-phase HF-LPME based on the number of phases involved. In 
the two-phase approach, the same solvent embedded on the HF pores is used as 
the AP. In the three phase extraction, the DP, the SLM and the AP solvents are all 
different. The organic solvent impregnated into the supporting pores of the HF in 
the three-phase system must always be immiscible in the other phases to ensure 
that the DP and the AP are not in direct contact (Asensio-Ramos et al., 2011; 
Chimuka et al., 2011; Ebrahimpour et al., 2011b). Either way, the AP now 
containing the analyte is directly injected into the analytical instruments for 
identification and quantification.  
 Advantages of the HF-LPME 2.2.2
The HF-LPME technique is simple and rapid, inexpensive, convenient, sensitive 
and has good precision and accuracy. Besides improvement in efficiency, the HF-
LPME could be done without any sample pre-treatment or further clean-up. This 
greatly reduces the number of steps involved. During extraction, the phases do not 
mix thus minimal volumes of solvents are required usually in the micro scale. The 
sample-to-acceptor volume ratio is elevated with the DP volume ranging in the 50 
µL – 1 L while the AP is usually less than 30 µL, typically 20 µL. This is essential 
for improvements in enrichment factors.  The low volumes used also make HF-
LPME a green extraction technique (Abadi et al., 2012; Bello-López et al., 2012; 
Dadfarnia and Shabani, 2010; Dziarkowska et al., 2008; Ghambarian et al., 2012; 
Han and Row, 2012; Lin et al., 2013; Pedersen-Bjergaard et al., 2002; Pena-
Pereira et al., 2010a; Poliwoda et al., 2010).  
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The tubular geometry of the hollow fiber provides a high packing density that 
offers a higher surface area per unit of volume. This coupled with the small 
thickness of the membrane (and hence small SLM volume) allows for effective 
mass transfer. Non-mixing of the phases eliminates possibilities of emulsion 
formation. However the sample, the extractant and the acceptor are in contact 
continuously. This provides a basis for a continuous, real-time process that can 
easily be automated and connected on-line to instruments (Abadi et al., 2012; 
Bello-López et al., 2012; Chimuka et al., 2010; Dadfarnia and Shabani, 2010; 
Ghambarian et al., 2012). 
The sample solution may be stirred, shaken or sonicated without any loss of the 
extracting liquid because it is mechanically protected and is immiscible with the 
DP and the AP. The small pore size of the HF becomes a clean-up barrier that 
prevents high molecular mass compounds from passing the liquid phase 
membrane during extraction (Pena-Pereira et al., 2010a; Tahmasebi et al., 2009). 
The HF-LPME technique is also suitable for analysis of a wide variety of 
inorganic and organic analytes over a wide range of polarity and pH with 
successful applications in environmental, forensic, food and pharmaceutical trace 
analysis and can be combined with almost any analytical technique (Abadi et al., 
2012; Al Azzam et al., 2010; Dziarkowska et al., 2008; Ghambarian et al., 2012; 
Han and Row, 2012; Lee et al., 2008; Lin et al., 2013; Poliwoda et al., 2010). The 
membrane is used once and then discarded to eliminate possibility of carryover 
problems and cross contaminations. The suitability of the HF-LPME as a sample 
preparation approach has been reported in several applications with publications 
reporting high sensitivity and selectivity (Al Azzam et al., 2010; Bello-López et 
al., 2012; Dadfarnia and Shabani, 2010; Ebrahimpour et al., 2011b; Ebrahimzadeh 
et al., 2011; Poliwoda et al., 2010; Quintana et al., 2004). 
The disadvantage of HF-LPME against traditional methods is that the rate of mass 
transfer is slower. It is only applicable in acidic or basic analytes with functional 
groups that are ionizable (Ebrahimzadeh et al., 2011; Lin et al., 2013; Tahmasebi 
et al., 2009). 
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 Critical parameters in HF-LPME  2.2.3
Since sample preparation is dependent on analyte and matrix effects, a suitable 
optimization procedure on preparation parameters is essential. A proper 
understanding of the desired extraction sequence during an HF-LPME process 
allows one to focus on optimizing essential parameters that lead to a successful 
extraction. Chimuka et al. 2010 clearly dissects the parameters that are deemed 
critical and need to be optimized when analysing ionizable compounds using an 
SLM extraction technique. The parameters are derived from the mass transfer 
kinetics associated with HF-LPME (Chimuka et al., 2010; Jönsson and 
Mathiasson, 2000). 
The aqueous phase pH needs to be optimized so that the analyte maintains 
electrical neutrality in the DP and exists as an ionized compound in the AP to 
prevent back-extraction (Chimuka et al., 2010; Dadfarnia and Shabani, 2010; 
Ghambarian et al., 2012; Pena-Pereira et al., 2010a). A basic compound will 
ionize under low pH. To maintain the neutrality and thus reduce its solubility 
within the DP, the DP pH should be adjusted to basic conditions.  The AP should 
be acidified in order to ionize and promote the dissolution of the basic analyte as a 
way of preventing back extraction.  For an acidic compound the DP has to be 
acidic while the AP is basic.  
 If the pKa value of the analyte is known, the pH value of the AP that maximizes 
extraction can be estimated. Likewise the pH value of the DP that enhances 
transfer to the AP can be predicted. For an acidic analyte, the pH of the AP should 
be higher than the pKa value by at least 3.3 units while for a basic analyte the AP 
pH is at least 3.3 units lower than the pKa value. The pH of the DP containing an 
acidic analyte must be 2 units less than the analyte pKa value. For a basic analyte 
the pH is at least 2 units more than the pKa value. These predictions allow for a 
focussed optimization merely meant to formally verify the best pH of the DP and 
AP. For example, Azzam et al., 2010 analysed ROSI, a basic drug with pKa 
values of 6.1 and 6.8 and optimized the DP pH at 9.5 by concentrating within pH 
6.5 – 11.5 (Al Azzam et al., 2010).  
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The type of supported liquid phase is also essential in HF-LPME depending on 
the polarity of the analyte and thinness of the supporting membrane. For optimum 
extraction, the embedded solvent must have low solubility in water, be immiscible 
in the DP and the AP and be easily immobilized in the HF pores. Several studies 
have used dihexyl ether as an SLM of choice following studies by Chimuka et al., 
2000 that identified dihexyl ether (DHE) and n-decane as transferring agents that 
give optimum extraction efficiencies (Chimuka et al., 2000). 
Agitation of the aqueous solution has shown to increase the extraction efficiency 
and reduce the extraction time by continuously exposing the extraction and 
diffusion surfaces of the membrane to fresh aqueous sample in the DP and the 
small volume of the AP respectively. Increase is attributed to diffusion as the 
limiting factor in mass transfer of the analyte. When solvent dissolution into the 
membrane becomes limiting, the efficiency becomes non-linear and finally 
plateaus.  Plateauing is also attained when the system reaches equilibrium and/or 
when almost all the analyte has been transferred into the AP. However excess 
vigorous shaking can lower extraction efficiencies because of loss of the SLM, 
solvent evaporation or creation of air bubbles that accumulate on fiber surface (Al 
Azzam et al., 2010; Chimuka et al., 2010; Pena-Pereira et al., 2010a).  
Other factors that might affect the extraction efficiency include extraction 
temperature, presence of humic acids and salting out effect (Bello-López et al., 
2012; Chimuka et al., 2010; Saaid et al., 2009). However these factors are not so 
important and are mainly influenced by other factors like the module and 
experimental design (for temperature), amount of trapped analyte (for humic 
substances) and amount of un-ionized analyte in the AP observed for longer 
extractions (for salt addition).  
 Carrier-mediated three phase HF-LPME for polar compounds 2.2.4
A carrier-mediated microextraction is essential for analytes that are too polar to 
freely dissolve into the hydrophobic supported liquid membrane, have multiple 
functional chargeable groups that can exist in different charged states at the same 
pH level and/or exist in their charged state in the entire pH range (Dziarkowska et 
al., 2008; Poliwoda et al., 2010; Romero et al., 2002). The purpose of a carrier 
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molecule is therefore to create a neutral moiety by binding to the analyte at the 
charged functional group. The carrier molecule must be hydrophobic so that it 
remains impregnated in the supported liquid membrane. The type of carrier 
molecule used depends on the charge of targeted functional group of the analyte. 
The quaternary ammonium salt, N-Methyl-N,N,N-trioctylammonium chloride 
(Aliquat 336) is preferred for combing with anionic functional groups while bis(2-
ethylhexyl) hydrogen phosphate (DEHPA) is common in extracting positively 
charged analytes (Dziarkowska et al., 2008; Poliwoda et al., 2010; Shariati et al., 
2009; Yamini et al., 2006). Other carriers that have been used include tris(2-
ethylhexy)phosphate (TEHP), Trioctylphosphine oxide (TOPO) and sodium 
octanoate (Fotouhi et al., 2011; Ghaffarzadegan et al., 2014; Ho et al., 2005, 2003; 
Li et al., 2014). The anionic DEHPA in Figure 4 was used in this research.    
         
Figure 4 Structure of DEHPA 
The mechanism of extraction is summarized in Figure 5. At the donor phase-SLM 
interface, the cationic analyte is picked up by the negatively charged carrier 
molecule. The neutralized and hydrophobic analyte-carrier moiety then migrates 
to the SLM-acceptor phase interface where it exchanges the analyte for a proton 
from the acceptor phase (Ho et al., 2003; Lin and Chen, 2006). Migration of the 
analyte from the donor phase into the acceptor phase depends on the availability 
of the counter protons. A high proton gradient between the donor phase and the 
acceptor phase is therefore crucial for effective extraction of the analyte.   
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Figure 5  The carrier-mediated extraction of MUS from an acidic donor sample to 
a more acidic acceptor phase 
 Quantification of muscimol in urine samples 2.3
Development of analytical methods for quantification of hallucinogenic 
compounds in urine samples of individuals suspected to have consumed 
hallucinogenic mushrooms whether intentionally or by mistake is essential in 
mushroom toxicology. The reliability of results for legal investigation of culprits 
or victims depends solely on the validity and the accuracy of the method used for 
quantification. MUS is excreted unchanged in urine and its quantification in urine 
can be used to prove prior exposure to Amanita mushrooms. Very few 
publications have reported quantifying MUS in human body fluids. Hasegawa et 
al., (2013) has reported solid phase extraction coupled to LC-MS to extract MUS 
from blood serum (Hasegawa et al., 2013). NMR-NOESY spectroscopy, capillary 
electrophoresis coupled with electrospray tandem mass spectrometry and cation 
exchanger with GC-MS with derivatization have also been reported (Deja et al., 
2014; Ginterová et al., 2014; Stříbrný et al., 2012). The present work targeted 
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extraction of muscimol and its two precursors, tryptophan and tryptamine using 
the HF-LPME approach in conjunction with HPLC-UV technique. The premise of 
this study was to contribute towards finding alternative quantification methods for 
hallucinogenic compounds in human body fluids that are simple, inexpensive and 
environmentally friendly.  
 Multivariate approaches to design of experiments 2.4
 Multivariate design of experiments 2.4.1
A design of experiment (DOE) is the process whereby a researcher makes 
decisions about how to answer their research questions through experimentation. 
A multivariate DOE is a research study that enables designers to predict 
interdependence of several variables that might affect a process output. It helps in 
turning any standard design into a robust one by providing a full insight of 
interaction between design elements that could cause problems in output if not 
monitored (Condra, 2001; Guo et al., 2007). Designers are then able to fix these 
problems and produce robust and higher yield designs prior to going into 
production.  
Use of multivariate approaches instead of the one-factor-at-a-time (OFAT) 
method or an expert trial-and-error helps to evaluate the effects and possible 
interactions of several factors. An OFAT approach varies one factor at a time 
while keeping all other factors constant (Czitrom, 1999; Mursyid and Saberi, 
2010). This approach disregards the possible impact of effects from interaction 
between factors. This becomes a disadvantage considering that one factor cannot 
produce the same response in the entire range of another factor.  
A multivariate experimental strategy involves two major steps; an initial screening 
process followed by an optimization stage. A factor screening design is meant to 
literally screen the parameters to determine the most important factors affecting a 
response among a selection of potential factors. When the vital-few have been 
selected, a further optimization step is done to maximize output. 
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 Multivariate Data Analysis Software 2.4.2
Several Windows compatible statistical packages that support a wide spectrum of 
multivariate data manipulation in offline mode are available. These include High-
D, the JMP (statistical software), MiniTab, R, Calc, PLS_Toolbox / Solo 
(Eigenvector Research), PSPP, SAS (software) SciPy for Python, SPSS,, Stata, 
STATISTICA, The Unscrambler, SmartPLS - Next Generation Path Modeling, 
MATLAB, Eviews, Prosensus ProMV, Umetrics SIMCA, OpenStat, DOE++ 
among others. Most of these packages are generally comparable with regard to 
functionality. The choice of use would mainly be based on the researcher’s scope 
of the experimental design expectations and the availability for free downloading. 
Some of these can be downloaded freely and can work offline in their full 
functional mode with no need for updates while some are limited in some way and 
may need updates every now and then.  
In this research Minitab 16 was used for experimental design and analysis. 
Minitab is a general purpose statistical software developed at the Pennsylvania 
State University by researchers Barbara F. Ryan, Thomas A. Ryan, Jr., and Brian  
L. Joiner in 1972. It can be freely downloaded for use in offline mode. Although 
the performance of the free version is limited in some way, it remains powerful 
enough for use in analysis of most experimental designs. Its user-friendly and 
simplified visual plots of results help identify patterns making interpretation of 
data an easy task. Minitab has Factorial designs and Taguchi designs available for 
screening purposes while optimization of the main effects is achieved using 
central composite approaches.  
 Factorial Designs  2.4.3
The most common factor screening design in experimental research is the factorial 
approach where there are multiple factors and the researcher is interested in their 
combined effect on the response output and need to be investigated 
simultaneously during the test (Atkinson et al., 2007; Cox and Reid, 2000; 
Franceschini and Macchietto, 2008). The objective of these designs is to identify 
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factors that have a significant effect on the response among factors that have been 
predicted to have an impact on an experimental response.  
The factors included in the design can be identified based on related publications. 
The levels of each factor for investigation can then be predicted based on the 
extraction method being developed, properties of the target analyte, the matrix 
and the chemicals to be used as well as the instrument response. A predictive first-
degree polynomial model is then used to sufficiently identify the important factors 
that have an impact on the response. A two level design involves identifying two 
points of a factor, one a lower value denoted by a negative (-) and the other the 
upper level denoted by a positive (+) sign. A three level will have three value 
points, a lower (-), a central (0) and an upper (+) value. For example, a two level 
design for temperature can be 30 and 60 while a three level design will involve 
investigation effect of temperature at 30, 45 and 60 value points. The choice of 
these limits can also be determined during preliminary studies where general 
OFAT studies are done. A factorial design can be classified as a full factorial or a 
fractional factorial. 
Full Factorial Designs  
As implied in its name, a full factorial experiment considers the predicted factors 
and all their interactions possible for the design. The entire treatment 
combinations of the factors and their selected level limits are investigated. They 
look at the effects that the predicted factors and all the interactions between 
factors have on the measured responses. 
The number of treatments is given by kl where l  is the number of factor levels 
and k is the number of factors. For example, if in our case, six (6) factors at three 
levels each are to be used it will require 729 different treatments (3
6
 = 729). It is 
obvious that the number of the levels of factors has a great effect on the size of the 
investigation. If two levels are used for each factor, only 64 experiments are 
needed to complete the screening process (2
6
 = 64).  For this reason, most of the 
designs involve only 2 levels of each factor compared to a general full factorial 
experiment with 3 or more levels. The main disadvantage with two level designs 
is that it only models a linear response ignoring any possibility of curvature.  
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Full Factorial designs are not desirable mainly because of the number of the 
experimental treatments that have to be done and the expense associated with it. 
An alternative is the use of fractional factorial designs. 
Fractional Factorial Designs 
During a fractional factorial design only a certain carefully chosen subset of the 
expected treatment combinations is investigated. A fractional factorial approach 
exploits the sparsity-of-effects principle to extract information about the most 
relevant features of the problem studied, while using a fraction of the effort of a 
full factorial design in terms of experimental runs and resources. The sparsity-of-
effects principle predicts that main effects and low order interactions (usually 
two-factor interactions) are of most interest, and are usually more significant than 
high order interaction terms. This principle is based on Vildredo Pareto’s 
probability distribution which predicts that about 80% of the observed phenomena 
are caused by about 20% of the factors. It is thus also referred to as the Pareto 
principle and refers to the idea that only a few effects in a factorial experiment 
will be statistically significant. The major assumption is that higher order 
interactions (those between three or more factors) are not significant and a 
compromise is taken when looking into interaction effects (Box and Hunter, 1961; 
Cochran and Cox, 1957; Gunst and Mason, 2009; Hinkelmann and Kempthorne, 
n.d.; Montgomery et al., 2009). This compromise is called confounding and 
involves aliasing main effects with high order interactions. If the effects are 
confounded, they cannot be estimated as single entities but are combined and 
predicted as effects due to interactions.  
The fractional factorial design equation 
Fractional designs are expressed in the form 
pk2 and allow for analysing k 
factors with only 
pk2  experiments where 2 refers to the factor levels, k is the 
number of factors investigated and p describes the size of the fraction of the full 
factorial used. Formally, p is the number of confounded effects and is used to 
describe the fractional design. A design with p such generators, is a fraction of the 
full factorial design and is described as a  
p2
1
 fractional factorial design. When p 
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= 1, the design is a half fractional factorial implying that only half of the full 
factorial experiments is needed or half of the treatment have been confounded. A 
12 k design requires only half as many experiments while a
22 k design requires 
only one quarter of the experiments. Where there is six factors to be investigated 
using a half fractional factorial design, 32 treatments are conducted (
3222 16   pk ). This is half of the 64 experiments that would have been 
required if a full factorial was used ).6422(
6 k  If a three level approach was 
used, it would require 243 experiments (3
6-1
 = 243). 
In identifying a best fractional factorial, a design’s resolution is used. The 
resolution of a design describes the extent of aliasing of effects in a fractional 
factorial design. A design’s resolution is therefore its ability to separate main 
effects and/or low-order interactions from one another. A design with higher 
resolution is considered better. 
The resolution of a fractional factorial design 
A resolution of the design relates to the minimum number of factor interactions 
that can be effectively predicted. The most important fractional designs are those 
of resolution III, IV, and V. Resolutions below III are not useful and resolutions 
above V are wasteful in that the expanded experimentation has no practical 
benefit in most cases and the bulk of the additional effort goes into the estimation 
of very high-order interactions which rarely occur in practice. Table 2 summarizes 
the possible resolutions and their acceptability in predicting interactions. 
When creating a factorial design in Minitab 16, the available designs with 
resolutions from III to VIII are displayed as shown in Figure 6. The green-coded 
resolutions represent the best fractional factorial for a specific number of factors. 
A full resolution occurs when all the possible interaction effects are investigated 
and no effect is confounded with another effect. A yellow-coded resolution is 
acceptable but not recommended while a red-coded one implies that the number 
of runs for that particular number of factors is unreliable because important 
information has been lost in confounded effects. The target is therefore to do the 
number of runs that give a green-coded resolution.  For example, when 
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investigating effects of six factors a full resolution and resolution VI will give 
reliable predictions. A full resolution is due to a full factorial where all the 64 
possible runs (2
6
 = 24) are conducted. A half-fractional factorial which requires 
32 experiments (2
6-1
 = 32) has a resolution of VI.   
Other multivariate screening designs include the Plackett-Burman Designs and the 
Taguchis Orthogonal Arrays (Atkinson et al., 2007; Cox and Reid, 2000; Miller 
and Miller, 2005; Ziegel, 2004). The Plackett-Burman approach was proposed by 
R. L. Plackett and J. P. Burman in the 1940s where only a few specifically chosen 
runs from two level fractional factorial designs are performed to investigate just 
the main effects. The interaction effects are not considered. Taguchis orthogonal 
arrays are highly fractional designs, used to estimate main effects using only a few 
experimental runs. Their minimized experimental runs are essential where main 
effects are predicted from three or more factor levels. Their main disadvantage is 
the presumption that interactions are non-significant. 
 Response surface designs for main factor optimization 2.4.4
Once the main effects have been identified, optimization of the factor values is 
achieved through a response surface design. A response surface approach predicts 
the main factor relationships that maximize response by fitting a second-order 
quadratic model within a specific factor value range (Bezerra et al., 2008; Carley 
et al., 2004; Khuri and Mukhopadhyay, 2010; Myers and Montgomery, 2003). A 
quadratic model is essential in predicting the optimum response output if the 
surface response has curvature. Unlike in DOE where the lower and upper values 
only are investigated, at least three values (or levels) of a factor are included in 
response surface designs. The two common approaches in response surface 
designs are the central composite design (CCD) and the Box-Behnken design 
while Doehlert designs for different factors studied at different levels and Mixture 
designs for mixture (or ingredient) proportions have been used for specific 
purposes (Atkinson et al., 2007; Chiao and Hamada, 2001; Cox and Reid, 2000; 
Ferreira et al., 2007; Miller and Miller, 2005).   
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The number of levels per factor depends on an alpha (α) value. The alpha value 
represents positions of some star (or axial) points on both axis of the design as 
represented in Figure 7. 
Table 2 Resolutions and their acceptability in predicting interactions 
Resolution Ability 
I 
Not useful: only one run (or value) is used to test the effect of a single 
factor and hence can't even distinguish between the high and low levels of 
that factor. 
II Not useful: serious confounding of vital effects. 
III 
Ability to estimate major effects.  However these may be confounded with 
two-factor interactions. 
IV 
Ability to estimate major effects and two-factor interactions. The major 
effects may be confounded with three-factor (or more) interactions while 
the two-factor interactions may be confounded with other two-factor 
interactions. 
V 
Ability to estimate major effects, two factor interactions and three factor 
interactions. Major effects may be confounded by four-factor (or more) 
interactions while the two-factor interaction effects may be with 
confounded with three-factor (or more) interactions. The three-factor 
interaction effects may be confounded with other two-factor interactions. 
 
VI 
Ability to estimate major effects not confounded with four-factor (or less) 
interactions. The two-factor interaction effects may be confounded with 
four-factor (or more) interactions while the estimated three-factor 
interaction effects may be confounded with other three-factor interactions. 
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Figure 6 Available factorial designs as displayed on Minitab 16  
  
Figure 7 Star points for a 2
2
 factorial as given by ±α on the axial lines. Modified 
from https://onlinecourses.science.psu.edu/stat503/node/59  
The CCD is the most popular mainly because it can have up to five levels per 
factor. A CCD needs to be spherical and rotatable. This is essential because if the 
level points are equidistant from the center of the design and so are the axial 
points then the variance (rotatability) of the responses from levels or axial points 
(positive or negative) is constant. Rotatability requires that α > 1 while sphericity 
is defined by k  where k is the number of vital factors (Atkinson et al., 2007; 
Ferreira et al., 2007).  
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Where there are 4 vital factors, 24  . The levels of each factor will therefore 
be investigated at -2, -1, 0, 1 and 2 representing five levels per factor where 0 
represents the mid-range value. For example, if the lower and upper temperatures 
of a CCD are set at 40 and 80, then the levels will be 20, 40, 60, 80 and 100. A pH 
4 – 6 range would be investigated at pH 3, 4, 5, 6 and 7.  
Analysis of a CCD is built on the foundation of the analysis of variance and a 
collection of models that partition the observed variance into components 
according to what factors the experiment must estimate or test. The F-test analysis 
is the basis for model evaluation of both single factor and multi-factor 
experiments. This analysis is commonly output as an ANOVA table. 
Once the CCD has been created it is then investigated experimentally. This allows 
for pairing of the main factors according to their extent of effect. The interaction 
effects of the paired factors are then investigated using response surface models. 
An empirical quadratic response surface model given by equation 1 is used to 
visualize the response surface through contour plots, surface plots and 
optimization plots of response.  
 

k
i
iii
k
ji
jiij
k
i
ii xbxxbxbby
1
2
11
0
   (1) 
Where y is the average peak area, k is the number of factors, b0 the intercept 
parameter, bi are the regression parameters for linear factor effects, bij are the 
regression parameters for interaction factor effects, and bii are the regression 
parameters for quadratic factor effects. For a k-number of factors, this model 
would have (k+1)(k+2)/2 number of parameters. For example, for two factors, 
there would be six parameters. 
The optimum value of the response occurs at the point of curvature and can be 
considered as a stationary point where the partial derivatives
0/......0/,0/ 2211  ii xyxyxy  . The optimum response can be a saddle 
point, a minimum point or a maximum point as shown in Figure 8 below. 
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Figure 8 Mesh contour plots showing a saddle point (a), a minimum point (b) and 
a maximum point (c). Modified from http://reliawiki.org/index.php/  
 Desirability functions  2.4.5
A desirability function is a model designed to measure how the optimized factor 
value satisfies the targeted response. The idea is that if a response output is 
dependent on various vital variables, then the effect of all the optimized values 
must fall within a desired limit otherwise such settings would be unacceptable 
(Del Castillo et al., 1996; Rueda et al., 2003; Wu et al., 2000). In desirability 
studies, a response output is assigned a desirability function denoted by ii yd
where iy is the 
thi response. The ii yd values range from zero to one. A ii yd value 
of one denotes an ideal situation while zero implies unacceptable settings. This 
range is dependent on setting a lower limit and a target value, or a target value and 
an upper limit, or both for the 
thi response depending on the goal of the method as 
shown Figure 9.  
 
Figure 9 Plots of desirability functions when the goal is to maximize the set 
response value (a), the goal is to minimize the set response value (b) or the goal is 
to set a target value for the response.  
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Each plot has its own mathematical definition. In this research, the goal was to 
maximize the response and the desirability was defined as equation 2.  
ii yd    

)/()( LTLyi     
Ty
TyL
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
1
    (2) 
T is the target value, L the set lower limit, iy the 
thi response and ω the weight of 
the factor. For a vital factor, ω is set to one and the ii yd function is linear. Almost 
all optimizations follow the ω<1 route where emphasis is on getting a value close 
to the optimum. The ω>1 approach requires that the target be achieved at all costs. 
When 0ii yd , the response iy  is below the set limit. Most desirability values are 
acceptable when 5.0ii yd . 
 A desirability function in which the effectiveness of an optimum point of two 
vital points is evaluated is called an individual desirability function because a 
single response is affected. A problem arises where the effect of several factors 
and factor levels on multiple responses are to be investigated.  
Each response output will have its own optimum factor values different from the 
optimum values for the other responses. This creates a practical concern because 
what is optimum for extraction of one compound cannot be optimum for the other 
compounds. This leads to a conflict of optimum settings considering that the aim 
of this research was to simultaneously optimize extraction of three compounds 
with different physicochemical properties. A balanced setting has to be found that 
would give the most appropriate response values for all the analytes. The 
composite desirability approach is used to compromise the factor values in order 
to satisfy an optimized response output.  
Composite desirability function 
A composite desirability function, D(Y) evaluates how the overall universal 
settings affect a set of responses. It gives an estimate of having a single factor 
value on multiple responses. It is therefore a function of the responses under a 
0 
1 
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single compromised value and can be summarized as equation 3. It is calculated 
as a geometric mean of individual desirabilities as given by equation 4 where m is 
the number of responses and, ω the weight of each factor. If all the factors are 
regarded as vital, then ω is set to 1. The composite desirability then simplifies to 
equation 5. The choice of universal main factor levels is dependent on the 
importance of each response and the purpose of the design experiment.  
 myyyfYD ,...,,)( 21          (3) 
)..../(1
2211
2121 ).....()( mm mm ydydydYD
     (4) 
m
mm ydydydYD
/1
2211 ).....()(         (5) 
 Method application to human body fluids 2.5
 Urine samples 2.5.1
An ideal urine specimen for method development must be adequately 
concentrated to ensure that matrix effects are catered for during detection of 
analytes of interest (Brunzel, 2013). The quality of the urine as given by its visual 
appearance depends on the person’s state of hydration and the length of time the 
urine is held in the bladder. Urination in the morning is mainly due to the body’s 
involuntary desire to discharge urine that accumulated in the bladder overnight. 
Such a specimen would have been returned in the bladder for at least 6 hrs and is 
ideal for testing matrix effects during method development for urinalysis. An 
early morning urine spacemen will therefore have maximum matrix effects. Such 
a specimen is ideal for testing the performance of a method.  
 Matrix-based calibration curves 2.6
Total analyte discrimination during extraction from biological samples is 
impossible. The profound effect of the matrix on the quality of an HPLC-based 
analysis requires that certain strategies be taken during method development as a 
way of accounting for matrix effects. The most accepted approach that 
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approximates the matrix effects is to construct a calibration curve for your 
analytes by spiking the sample matrix with analyte standards at different 
concentration levels and extracting the analytes back out. The instrument response 
over a specific range of spiking concentrations is then plotted against the spiking 
concentrations giving a matrix-based calibration curve. Other calibration 
approaches that have been introduced in urinalysis include the kinetic calibration 
approach and the desorption kinetic calibration approach initially developed for 
solid phase micro-extractions (Chen and Pawliszyn, 2004; Cui et al., 2012; Xu et 
al., 2015). 
 Method validation parameters 2.7
Various approaches that include linearity, repeatability and reproducibility, limit 
of detection (LOD) and limit of quantification (LOQ) are used to validate the 
suitability of a method for its intended application.  
 
 Linearity 2.7.1
Linearity is tested as a linear regression model between the instrument’s response 
to the extracted analyte and the spiking concentration. The coefficient of 
determination denoted by R² ( r² if the point of y intersection of the calibration 
curve is specified) is used to evaluate how the regression line fits the data set or 
how close the residual data are to the fitted regression line. The R² values range 
from 0 to 1 and are an indication of the degree of certainty when predicting a 
dependent variable using the linear regression equation. An R² value of 0 implies 
that the dependent variable cannot be predicted using the linear regression line 
from the independent variable. An R² value of 1 indicates that the regression line 
passes through all residual points and hence the prediction is without error (Miller 
and Miller, 2005). 
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 Limits of detection and quantification  2.7.2
A limit of detection (LOD) is generally the minimum amount of an analyte that 
can be reliably distinguished from a blank sample but not necessarily quantifiable 
under specific experimental conditions. An LOD can be instrument-based or 
method-based depending on why the minimum amounts of the analyte need to be 
determined. An instrument-based LOD is meant to evaluate the instrument’s 
sensitivity towards an analyte in the absence of interference (or using standard 
solutions) while a method-based approach is used to test the detection capabilities 
of a method by taking into consideration the presence of interferences. The 
method-based LOD is a sample specific approach dependent on both the 
instrument’s minimal response and the sample preparation techniques used. 
Determination of the LOD can be empirical through visual evaluation of the peak 
responses or statistical through calculations that use the standard deviation (SD) 
of the response. There are three common methods used in estimation of analyte 
detection limits (Box et al., 2005; Guideline, 1995; Shrivastava and Gupta, 2011; 
US Food and Drug Administration, 1996). 
Common in chromatographic responses that exhibit baseline noise is the signal to 
noise (S:N) method. The highest peak-to-peak noise around the retention time of 
the analyte is measured and the concentration of the analyte that would give three 
times the peak height of the noise is estimated using the calibration curve 
regression equation. The predicted concentration is then injected and the true S:N 
ratio calculated using equation 6. 
hHLOD /2          (6)  
Where H is the peak height of the prescribed analyte concentration and h
is the peak-to-peak background noise 
The S:N approach is limited to instrument detection limits where the instrument 
background noise is of main concern rather than the presence of interfering 
compounds. This approach was not applicable in our method development 
considering that percentage matrix effects were profound. 
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Another approach is the linear regression method. It estimates the LOD from the 
linear regression equation. For a calibration curve with linear regression equation
cbxy  , equation 8 is used. 
bSDLOD response /3         (8) 
Where responseSD   represents the standard deviation of y, and b  the slope of the 
calibration curve. These values can be obtained using the LINEST function in 
Excel. 
This approach is only applicable where there is no background noise or 
interference, a situation that is impossible in a typical analytical procedure.  
Finally is the blank determination procedure which estimates the LOD and LOQ 
from the mean of the blank and the standard deviation of the blank. This approach 
expresses the LOD as the sum of the average blank response and its three fold 
standard deviation. This is mathematically expressed as equation 9. 
blankblank SDmeanLOD 3        (9) 
This is a method-based approach in which both the baseline noise and the 
interference are taken into account. The blank determination became our detection 
limit determination method considering the enhancing effect of the matrix 
experienced in our developed method. The limit of quantification (LOQ) was then 
calculated using equation 10. 
blankblank SDmeanLOQ 10        (10) 
The LOQ is the minimum amount that can be confidently ascertained with a 
degree of precision and accuracy using a linear regression model if the analyte 
were existent in the sample. 
 Other method validation parameters 2.7.3
Repeatability and reproducibility of a method are essential precision and accuracy 
parameters and are determined comparatively as intra-day and inter-day 
reputations of the response output. Other parameters that are considered when 
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attempting to demonstrate the applicability of a developed method include 
specificity, selectivity, accuracy, robustness, extraction range and system 
suitability (Miller and Miller, 2005; Shrivastava and Gupta, 2011; Ziegel, 2004).  
34 
 
3 RESEARCH OBJECTIVES 
 General objectives         3.1
The main objective of this research was to develop a hollow fibre-based liquid 
phase microextraction of hallucinogenic compounds from human urine followed 
by chromatographic quantification. 
 Specific objectives 3.2
(1) To extract and quantify muscimol and its precursors, tryptamine and 
tryptophan from urine samples using HF-LPME coupled to HPLC-UV 
 
(2) To select chromatographic conditions for the separation of hallucinogenic 
alkaloids 
 
(3) To use multivariate factorial designs in identifying essential HF-LPME 
parameters 
 
(4) To use central composite designs to optimize levels of essential parameters 
that would maximize enrichments of analytes during HF-LPME 
 
(5) To test the developed method on spiked human urine 
 Justification 3.3
Even though the hallucinogenic effect has low toxicity and is non-addictive, the 
potential risk and potential fatality at elevated levels coupled with documented 
evidence on the continued abuse and in some cases poisoning by hallucinogenic is 
a cause for concern (Tsujikawa et al., 2007; van Amsterdam et al., 2011). Very 
few publications have been reported on quantification of MUS in urine samples. 
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Development of quantification methods that are simple, inexpensive yet effective 
and environmental friendly is a necessity. The high extraction efficiencies and 
selectivity and sensitivity of the follow fibre-based liquid phase microextraction 
reported in literature offers a good starting point for considering its applicability 
in the extraction of polar hallucinogens from biological matrices.  The target 
compounds have never been analysed using this approach. The results of the study 
can offer better alternatives for analysis of hallucinogenic alkaloids in the fields of 
forensics and food toxicology.  
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4 RESEARCH METHODOLOGY 
 Chemicals and reagents 4.1
All compounds except Psilocin (PSI) were purchased from Sigma-Aldrich 
(Johannesburg, South Africa). PSI in powder form was obtained via the 
Department of Forensic Sciences, Johannesburg, South Africa. Muscimol (MUS), 
Tryptophan (TRP), Tryptamine (TA) and 3,4- Dimethoxyphenethylamine 
(DMPE) were all purchased in powder form while Phenethylamine (PEA) and 
Hordenine (HO) were in liquid form.  
Ammonium acetate, di-(2-ethylhexyl)phosphoric acid (DEHPA), dihexylether 
(DHE), hydrochloric acid (HCl), ammonium formate, acetic acid, acetone and 
formic acid were also from Sigma-Aldrich (Johannesburg, South Africa).  HPLC-
grade acetonitrile (MeCN), methanol (MeOH) and tetrahydrofuran (THF) were 
obtained from Merck Chemicals (Pty) Ltd, Johannesburg, South Africa. 
Deionized water (d-H2O) used to prepare standard solutions and the mobile phase 
was purified from a Milli-Q-RO4 system (Millipore, Bedford, MA, USA).  
 Instrumentation 4.2
A Bishoff LC-CaDI 22-14 system (Leonberg, Germany) with a Lambda 1010 UV 
detector set at 280 nm was used for quantification of the analytes. Elution was 
done isocratically with injection of the analyte solutions done using a Rheodyne 
Series 7725i manual injector with a 10 µL sample loop. Data acquisition and 
processing was done on McDAcq32 version 2.4.702 software. Separation of 
analytes was done on a Waters Ascentis Express HILIC with dimensions 10 cm x 
2.1 mm x 2.7 μm using a mobile phase that had been buffered at pH 3 with 
formate. Prior to elution, the column was equilibrated with the mobile phase for at 
least 30 mins to allow for creation of a pseudo-stagnant aqua layer on the surface 
of the HILIC column. After investigation the column would then be washed with 
a MeCN: H2O mobile phase with a same organic component composition as the 
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last mobile phase used for elution and finally 100% MeCN for 10 mins. 
Degassing of the mobile phase was done using an online Degasys DG-1310 from 
Uniflows Co., Ltd, Tokyo, Japan. A Transsonic T460 D-78224 by Elma, Germany 
was used for all sonication. All pH recordings were done using an HQ430d 
benchtop flexi meter by Hach Company, Loveland Cc. USA. For stirring of the 
sample solution, a multi-point magnetic stirrer MS-MP8 by Daihan Scientific 
Co.,Ltd, Seoul, South Korea was used. A galvanized steel binding wire by Mac 
Indies Company, South Africa branded as NPS/BW-071-50 with 0.71 mm 
thickness was used for holding hollow fibres in samples solutions during 
extraction.  
 Preparation of standard solutions and buffered mobile phase 4.3
Analyte stock solutions of 1000 μg mLˉ¹ were prepared separately in 100 ml 
methanol and kept in the refrigerator at 4⁰C when not used and brought to room 
temperature just before use. New stock solutions were prepared after every 
fourteen days. 
For instrument calibration, separation was achieved when the analyte stock 
solutions were dissolved in THF and eluted at 0.4 mL min
-1
 with a pH 3-buffered 
mobile phase consisting of MeCN: Buffer 90:10% (v/v) 10 mM formate. This 
mobile phase-buffer composition was freshly prepared on a daily basis and when 
needed by mixing 4 mL of 500 mM ammonium formate with 16 mL of 500 mM 
formic acid and making up to 200 mL with MECN.   
At pH 3, all our research compounds were positively charged on the basic N atom 
while the –OH group remained neutral except for TRP whose pKa (OH) value 
made it zwitterionic with however a zero global net charge. The acidic acceptor 
phase to be injected into HPLC-UV system was first diluted into MeCN as a 
modifier and finally into THF in order to achieve separation. 
38 
 
 Chromatographic conditions        4.4
Several columns and mobile phases were investigated in order to find suitable 
chromatographic conditions that could separate the analytes. The interest in 
selecting column(s) that can be used in chromatographic separation of 
hallucinogenic alkaloids was evoked by the failure of the reverse phase columns 
in separating our target analytes during preliminary studies. While most of the 
hallucinogen extractions have used liquid chromatographic separations in reverse 
phase mode (Becker et al., 1999; Berge, 1999; Bigwood and Beug, 1982; 
Björnstad et al., 2009; Brandt and Martins, 2010; Chen et al., 2011; Gennaro et 
al., 1997; Kamata et al., 2010; Lindenblatt et al., 1998; Manevski et al., 2010; 
Marcano et al., 1994; Martin et al., 2014; Pichini et al., 2014; Saito et al., 2005; 
Tsujikawa et al., 2007; Wurst et al., 1992), it was observed that there has never 
been an attempt to simultaneously quantify muscimol and psilocin despite being 
identified as the active agents responsible for the hallucinogenic effects of 
mushrooms. The extent of separation of seven polar hallucinogenic tryptamine 
and phenethylamine derived alkaloids containing a basic N atom that becomes 
protonated at low pH values was investigated on two alkyl reverse phase (RP-
alkyl) columns, a reverse phase amide (RP-amide), two phenyl-based reverse 
phase columns and a HILIC column.  
The physicochemical properties of the compounds and the columns used are given 
in Figure 10 and Table 3 respectively. The choice of the alkyl RP columns was 
based on the fact that most liquid chromatographic separations of hallucinogens 
are based on this type of columns. Active phase-analyte interactions are 
exclusively hydrophobic. The RP-Amide was chosen for the presence of the 
embedded polar amide group that is expected to improve retention of polar 
analytes and also because it has always been viewed as one of the first definite 
alternative to C18 columns for analysis of polar compounds. 
The phenyl-based columns were targeted for the phenyl group that might interact 
through τ-τ interactions available through the phenyl ring with the cyclic groups 
of the target compounds. The negatively charged fused-core silica Ascentis 
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Express HILIC choice was based on studies by Chirita et al. 2010 (Chirita et al., 
2010) and recommendations by McCalley 2010 (McCalley, 2010) considering 
that our model compounds have positively charged N atoms at low pH values. 
 Calibration of the HPLC-UV 4.5
Six calibration standards between 0.5 µg mL-1 and 10 µg mL-1 were used in 
construction of external calibration curves for muscimol, psilocin, tryptophan and 
tryptamine. Each calibration standard was injected in triplicate as part of quality 
assurance. Standard deviations were calculated and used for error bars in 
constructing calibration curves. The coefficient of determination (R²), limits of 
detection (LOD) and the limits of quantitation (LOQ) were also determined and 
reported.  
 Hollow fibre preparation  4.6
Q 3/2 Accurel 200/600 Accurel® PP polypropylene hollow fibre tubings having a 
wall thickness of 200 µm, 600 µm inner diameter and a pore size of 0.2 µm 
supplied by Membrana GmbH (Wuppertal, Germany) were used. 8 cm long strips 
of the fibre were cut using a scalpel with a detachable size 10 Swann-Morton 
surgical blade. An 8 cm long fibre has an internal volume of 22.6 µL. The fibre 
would then be heat sealed on one end.   
 
 
40 
 
 
 
       Figure 10   Chemical structures of the model compounds and their relevant physical properties 
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 Table 3 Properties of the six columns used 
 All information was obtained from Sigma-Aldrich, South Africa
 Discovery C18 Discovery  
HS C18 
Gemini Hexyl  
Phenyl 
Waters Spherisorb 
Phenyl 
Ascentis  
RP-Amide C16 
Waters Ascentis 
Express HILIC 
Mode of 
chromatography 
Reversed 
phase (RP) 
Reversed 
phase (RP) 
Reversed 
phase (RP) 
Reversed 
phase (RP) 
Reversed 
phase (RP) 
Hydrophilic 
interaction  
Mode of 
interaction 
Hydrophobic Hydrophobic π-π interactions 
and hydrophobic 
π-π interactions 
and hydrophilic 
H-bonding Hydrophilic 
Particle platform Silica Silica Silica Silica Silica Fused-Core 
Active group C18 (octadecyl) C18 (octadecyl) Phenyl-hexyl Phenyl ring with 
short butyl spacer 
Amide, alkyl Bare silica with 
silanols 
Feature Endcapped Endcapped Endcapped Endcapped Endcapped Not endcapped 
L × I.D. 25 cm × 4.6 mm 15 cm × 2.1 mm 25 cm × 4.6 mm 25 cm × 4.6 mm 25 cm × 4.6 mm 10 cm × 2.1 mm 
Particle size(μm) 5 5 5 5 5 2.7 
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 HF-LPME procedure 4.7
The HF-LPME procedure included adding 10 mL of the sample solution into a 15 
mL sample vial. The sample solution was adjusted to the appropriate pH value 
using dilute NaOH or HCl. The 8 cm long hollow fibers were ultra-sonicated in 
acetone for 60 mins to remove any contaminants. Thereafter, they were removed 
and dried by evaporation at room temperature on clean paper towels. About 30 µL 
of AP of appropriate composition was withdrawn using a 50 µL syringe. The 
syringe needle was inserted into the unsealed end of the HF segment. The AP was 
transferred into the HF until bubbles of the solvent appeared on the walls of the 
HF. The bubbles were wiped off using paper towel to remove excess AP solvent 
on the outside. The syringe needle was then replaced with a wire acting as hook 
for hanging the fiber into solution. The fiber containing the AP was then dipped 
into the organic phase with appropriate composition for 10 seconds to embed the 
pores of the HF with DEHPA impregnated in a DHE solution. Care was taken not 
to lose any AP solution due to small back pressure once fibre was dipped into the 
impregnated organic phase. The SLM-embedded fibre was then taken out and 
dipped in de-ionized water for 5 seconds in order to wash away the extra organic 
solvent from the surface of the HF.  
The HF containing the AP and the embedded solvent membrane was finally 
placed in the vial containing the sample solution. The cap of each of the sample 
vials was pierced to allow the supporting wire to be tightly held in order to 
support the HF. The complete extraction setup was agitated using a magnetic 
stirrer. After a specific time of extraction, the stirrer was switched off, the HF 
removed from the sample solution and the wire carefully replaced by another 50 
µL HPLC syringe with the piston pushed down.  
With slight pulling of the piston to prevent any loss of the AP, the sealed end of 
the hollow fiber was cut and the AP drawn back into the syringe by pulling up the 
piston. Only 20 µL of the AP would be collected and what remained was 
discarded with the HF. The collected AP solution would then be divided into two 
aliquots each 10 µL and diluted accordingly for injection into the HPLC-UV 
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system. Volumes of diluents used were depended on the extent of enrichment of 
the analyte into the HCl acceptor phase. Thus one portion of the acceptor phase 
was prepared and analyzed for MUS and TRP while the other was for analysis of 
TA and PSI whose enrichments were very high compared to those of MUS and 
TRP and needed to be diluted more. Table 4 summarizes the amounts of diluents 
used. The schematic diagram in Figure 11 summarizes the general procedure. 
Table 4 Dilution of acceptor phases for injection into the HPLC system 
Target 
analytes 
Volume of 
AP (µL) 
Volume of  
MeCN (µL) 
Volume of 
THF (µL) 
Dilution factor 
Mus & TRP 10 10 40 6 
TA & PSI 10 20 500 53 
 
 Efficiency of the method 4.8
Method efficiency was calculated as the extent of enrichment of the analytes from 
the donor phase to the acceptor phase. Poliwoda et al. 2010 declares that for 
analytical purposes, the enrichment factor (EF) is more important than the 
extraction efficiency (Poliwoda et al., 2010). The sole purpose of this research 
was quantification of MUS and its precursors. The EF values were calculated 
using equation 11. 
EF   =    concentration of analyte in the acceptor phase after extraction    (11) 
  concentration of analyte in the donor phase before extraction 
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Figure 11  Schematic diagram for the HF-LPME procedure  
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 Multivariate optimization of the HF-LPME parameters 4.9
 Screening experiments using a half fractional factorial design   4.9.1
A two-level half fractional factorial design denoted by 12 k was created in Minitab 
16 in which the number of factors (k) was set to six. The six factors identified 
from related studies and publications that are involved in carrier-mediated HF-
LPME were donor phase pH, acceptor phase concentration, supported liquid 
membrane composition, NaCl content, stirring rate and extraction time. The half 
fractional factorial had a green-coded resolution of VI. This design needed thirty 
two experiments to be run. The parameters of the design are summarized in Table 
5.      
Table 5 Summary of a fractional factorial design used 
Design Runs Resolution 2
k-p 
½ fraction 32 VI 2
6-1 
 
The donor phase pH, acceptor phase concentration, SLM composition, extraction 
time, stirring rate and %NaCl were coded as A, B, C, D, E and F respectively. 
Table 6 shows the lower and upper limits set for each factor. The choice of DP pH 
limits was based on properties of the carrier molecule and the target analytes. The 
carrier embedded on the SLM is anionic so the analytes are expected to exist in 
their cationic state in the donor phase for effective transportation by the carrier. 
Our analytes were basic at the peripheral N atom and were expected to be cationic 
in acidic conditions. The carrier used, DEHPA is itself acidic and if the donor 
phase was to be basic (pH > 7), the carrier would be lost due to neutralization. The 
choices of SLM composition levels were based on publications while the levels of 
the other four factors were based on the researchers’ preliminary studies.   The 
designs were then investigated for TA (and PSI) and MUS (and TRP).  
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Table 6 Lower and upper levels for the six factors 
 Lower level Upper level 
DP pH 3 7 
AP concentration (mM HCl) 10 100 
SLM composition (%w/w) 5 20 
Extraction time (mins) 10 30 
Stirring rate (rpm) 600 800 
NaCl content (%w/v) 0.001 0.01 
  
An unfolded design with randomized runs was created in Minitab. The coded 
design was summarized in form of Table A1 while Table 7 shows the resolution 
VI types of confounding for the six factors. Table 7 shows that the chosen design 
could estimate main factors that were only confounded with at least five-factor 
interaction effects. The estimated two-factor interactions were free from 
confounding with three-factor (or less) interactions. However the three-factor 
interactions estimated by this design had been aliased with other three-factor 
interactions. The uncoded levels of each factor were specified and the signs 
represented in Table A1 were enumerated as shown in Table 8. 
Once the design had been constructed using two levels (a lower value and an 
upper value) of each factor, triplicate experiments were carried out for the 32 runs 
and the peak areas statistically analyzed using ANOVA.  
The extent of the factor effects on the EF values was then analyzed using Pareto 
charts of effects, normal plots of effects and the main effects plots for averages. 
The three different plots of effects were used to identify those parameters having a 
huge impact on the enrichment factor for the extraction of each analyte from 
spiked samples. Only thirty largest factor effects were represented in the three 
plots. 
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 Table 7 Alias structure of the 2
6-1
 fractional factorial design for six factors 
Factor interactions Minimum number of confounding factor combinations 
I ABCDEF 
A BCDEF 
B ACDEF 
C ABDEF 
D ABCEF 
E ABCDF 
F ABCDE 
AB CDEF 
AC BDEF 
AD BCEF 
AE BCDF 
AF BCDE 
BC ADEF 
BD ACEF 
BE ACDF 
BF ACDE 
CD ABEF 
CE ABDF 
CF ABDE 
DE ABCF 
DF ABCE 
EF ABCD 
ABC DEF 
ABD CEF 
ABE CDF 
ABF CDE 
ACD BEF 
ACE BDF 
ACF BDE 
ADE BCF 
ADF BCE 
AEF BCD 
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Table 8 Design of experiment summary showing uncoded randomized runs when 
a 2
6-1
 fractional factorial was designed with each factor having two levels; a lower 
level and an upper level 
Run 
Order 
DP 
pH 
AP 
concentration 
(mM HCl) 
SLM 
composition 
(% w/v) 
Extraction 
time (mins) 
Stirring 
rate (rpm) 
NaCl 
content  
(% w/v) 
1 3 100 5 10 600 0.01 
2 7 10 5 10 800 0.001 
3 3 10 20 30 600 0.001 
4 7 100 20 30 800 0.01 
5 3 100 5 30 800 0.01 
6 7 100 5 10 600 0.001 
7 3 10 20 30 800 0.01 
8 3 10 20 10 800 0.001 
9 7 10 5 30 800 0.01 
10 7 10 20 10 800 0.01 
11 3 10 5 10 600 0.001 
12 7 10 20 30 800 0.001 
13 3 10 5 30 600 0.01 
14 3 10 20 10 600 0.01 
15 7 10 20 30 600 0.01 
16 3 100 5 10 800 0.001 
17 3 100 20 30 800 0.001 
18 7 10 5 30 600 0.001 
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19 7 10 5 10 600 0.01 
20 7 100 5 10 800 0.01 
21 3 10 5 30 800 0.001 
22 7 100 5 30 600 0.01 
23 7 100 5 30 800 0.001 
24 3 100 20 10 600 0.001 
25 3 100 20 30 600 0.01 
26 3 100 5 30 600 0.001 
27 7 10 20 10 600 0.001 
28 3 10 5 10 800 0.01 
29 7 100 20 30 600 0.001 
30 3 100 20 10 800 0.01 
31 7 100 20 10 600 0.01 
32 7 100 20 10 800 0.001 
 
 Optimization experiments using central composite designs  4.9.2
After identifying four factors as essential for the HF-LPME of the analytes, a 
spherical and rotatable CCD was created by setting 24  as shown in Figure 
12. 
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Figure 12  Designing a spherical rotatable central composite approach. X1-4 refers 
to the four vital factors identified from fractional factorial design.  
From the design in Figure 12, it could be shown that there were eight star (axial) 
points represented by either ±1α or ±2α. There were sixteen factorial points that 
existed where the four factor lines (X1, X2, X3 and X4) touched the sides and the 
vertices of the small square and the big square. Only one centre point could be 
seen but if Fig 12 had been observed from two or three dimensional, a total of six 
centre points would have been observed. The overall number of points was 
therefore thirty (16 factorial points, 8 star points and 6 centre pints). This design 
was simplified mathematically using equation 12 below in which 2
k
 represented 
the factorial points, k2  the star points and C the centre points. N represents the 
total number of points. 
CkN k  22         (12) 
Thus thirty runs were carried out for each compound in order to classify the extent 
of each of the four vital factors. The levels of each factor were code-set using α = 
±2 giving a 5-factor level design represented as -2, -1, 0, 1 and 2 where 0 
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represented the mid-range value and ±1 were factor levels chosen by the 
researcher.  
Central composite design for main factors for MUS (and TRP)   
The chosen factor levels that were entered into Minitab in order to create the 
design are given in Table 9 while Table 10 shows the actual levels used for each 
factor. The randomized coded design was represented as shown in Table A2. The 
uncoded central composite design for the four essential factors for the extraction 
of MUS is represented in Table 11.  
Table 9 Factor levels that were entered into Minitab when creating the CCD for 
the main factors 
  
DP pH 
AP concentration 
(mM HCl) 
SLM composition 
(% w/w) 
Stirring rate 
(rpm) 
Set lower level 4 50 10 600 
Set upper level 6 100 20 800 
 
Table 10 Actual factor levels of the main factors that were experimentally 
investigated  
Alpha (α) value -2 -1 0 1 2 
DP pH 3 4 5 6 7 
AP concentration (mM HCl) 25 50 75 100 125 
SLM composition (% w/w) 5 10 15 20 25 
Stirring rate (rpm) 500 600 700 800 900 
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Table 11 Randomized central composite design for the essential factors at α = 2 
 
Run 
 
DP pH 
AP concentration 
(mM HCl) 
SLM composition 
(% w/w) 
Stirring rate 
(rpm) 
1 3 75 15 700 
2 5 125 15 700 
3 5 75 15 500 
4 5 25 15 700 
5 5 75 5 700 
6 5 75 25 700 
7 5 75 15 900 
8 5 75 15 700 
9 5 75 15 700 
10 7 75 15 700 
11 4 100 10 800 
12 5 75 15 700 
13 5 75 15 700 
14 6 50 10 600 
15 6 50 20 600 
16 4 100 20 800 
17 6 100 20 600 
18 4 50 20 600 
19 4 50 20 800 
20 6 100 10 800 
21 6 50 20 800 
22 4 50 10 800 
23 5 75 15 700 
24 4 50 10 600 
25 6 50 10 800 
26 6 100 20 800 
27 4 100 10 600 
28 6 100 10 600 
29 5 75 15 700 
30 4 100 20 600 
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Central composite design for main factors for TA (and PSI) 
For the extraction of TA, extraction time replaced stirring rate in the four main 
factors. Its values that were set on Minitab were 40 and 80 mins. This resulted in 
five levels of 20, 40, 60, 80 and 100 mins. The coded and uncoded central 
composite designs for the optimization of the vital factors for the extraction of TA 
are represented in Table A3 and Table 12 respectively.  
The response from varying each factor was standardized and Pareto charts of 
standardized effects and normal plots of standardized effects were plotted in order 
to visualize the extent of effect of each of the four vital factors. The factors were 
then grouped into pairs accordingly.  
The combined effect for each of the paired factors for the extraction of each 
analyte was then investigated over a specific range of factor values. The number 
of values in the specified range of each factor was decided by the researcher. The 
paired factors and the factor levels investigated for the individual extraction of 
analytes are shown in Table 13 – 19. Only one pair could be investigated for PSI.  
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Table 12 Randomized uncoded central composite design for the essential factors 
for TA  
 
Run 
 
DP pH 
AP concentration 
(mM HCl) 
SLM composition 
(% w/w) 
Extraction time 
(mins) 
1 5 75 15 100 
2 7 75 15 60 
3 5 75 5 60 
4 5 75 15 20 
5 5 75 15 60 
6 5 25 15 60 
7 3 75 15 60 
8 5 75 25 60 
9 5 75 15 60 
10 5 125 15 60 
11 4 100 10 40 
12 6 100 10 40 
13 6 100 20 80 
14 5 75 15 60 
15 4 100 20 80 
16 6 50 10 80 
17 6 100 10 80 
18 4 100 10 80 
19 4 50 20 40 
20 4 50 20 80 
21 4 100 20 40 
22 4 50 10 40 
23 6 100 20 40 
24 5 75 15 60 
25 6 50 10 40 
26 5 75 15 60 
27 6 50 20 80 
28 4 50 10 80 
29 6 50 20 40 
30 5 75 15 60 
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Table 13 Factor levels for the investigation of the combined effect of DP pH and 
stirring rate in the extraction of MUS 
DP pH Stirring rate (rpm) 
3 500 600 700 800 900 
4 500 600 700 800 900 
5 500 600 700 800 900 
6 500 600 700 800 900 
 
Table 14 Factor levels for the investigation of the combined effect of AP 
concentration and SLM composition in the extraction of MUS 
AP concentration 
(mM HCl) 
 
    SLM composition (% w/w) 
30 5 10 15 20 
50 5 10 15 20 
75 5 10 15 20 
100 5 10 15 20 
 
Table 15 Factor levels for the investigation of the combined effect of DP pH and 
AP concentration in the extraction of TA 
DP pH         AP concentration (mM HCl) 
3 50 100 150 200 
4 50 100 150 200 
5 50 100 150 200 
7 50 100 150 200 
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Table 16 Factor levels for the investigation of the combined effect of SLM 
composition and extraction time in the extraction of TA 
SLM composition 
(% w/w) 
 
      Extraction time (mins) 
5 30 40 60 80 
10 30 40 60 80 
15 30 40 60 80 
20 30 40 60 80 
 
Table 17 Factor levels for the investigation of the combined effect of donor phase 
pH and stirring rate in the extraction of TRP 
DP pH Stirring rate (rpm) 
3 500 600 700 800 900 
4 500 600 700 800 900 
5 500 600 700 800 900 
6 500 600 700 800 900 
7 500 600 700 800 900 
 
Table 18 Factor levels for the investigation of the combined effect of AP 
concentration and SLM composition in the extraction of TRP 
AP concentration 
(mM HCl) 
 
SLM composition (% w/w) 
30 5 10 15 20 
50 5 10 15 20 
75 5 10 15 20 
100 5 10 15 20 
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Table 19 Factor levels for the investigation of the combined effect of SLM 
composition and extraction time in the extraction of PSI 
SLM composition 
(% w/w) 
 
Extraction time (mins) 
5 30 40 60 80 
10 30 40 60 80 
15 30 40 60 80 
20 30 40 60 80 
 
The response results were then transferred into Minitab. An empirical second 
order response surface model was used in which the response was plotted against 
the combined effect of simultaneously varying the paired factor levels. The 
quadratic response surface model was estimated by setting the k number of factors 
in equation 4 to two. Thus the quadratic response models for each paired factors 
for each analyte were obtained by simplifying the parameters of equation 1 to six 
as represented in equation 13. Regression coefficients for response estimated from 
Minitab using data in uncoded units were used as bi and bij values. 
2112
2
222
2
11122110 xxbxbxbxbxbby     (13) 
The resulting surface was visualized using contour plots and surface plots of 
response. Optimization plots which showed points of curvature for each model 
were also created. The optimum factor values for each pair were identified as the 
points of curvature on the plots. Included in the optimization plots were the 
individual desirabilities of the predicted optimum values of each pair factor in 
maximizing the desired response output.  
 Applying optimized method to spiked water samples 4.9.3
Individual analyte extraction from spiked water samples    
The optimum values for the four factors where then investigated practically by 
applying them for the extraction of individual analytes from spiked water samples. 
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The response output given as EF values was then compared with the EF values 
predicted in the optimization plots. 
Simultaneous extraction of analytes from spiked water samples   
The purpose of this method development was to simultaneously quantify MUS, 
TA and TRP from samples. However, each main factor had its own optimum 
factor level for the extraction of each analyte using HF-LPME from samples. 
There was a need to assess the importance of each analyte response in order to 
assign appropriate values for the factors during simultaneous quantification. In 
this case, the enrichment factor for MUS was deemed important mainly because 
muscimol had the lowest EF and it was the project’s main analyte because of its 
hallucinogenic properties. The target was therefore to maximize the EF value of 
MUS. The optimum parameters of MUS were then set as the composite factor 
values for simultaneous extraction. These compromised factor values were 
changed from optimization plots in Minitab. The extent of the effect of the overall 
universal settings on the three analyte response outputs was evaluated using a 
composite desirability function, D(Y) in which the geometric mean of individual 
desirabilities for each analyte response output was calculated using equation 5 
where md represented the individual desirability for changing the optimized factor 
levels in a paired interaction to universal settings and m  the total number of 
responses due to paired factors for all the three analytes. 
These MUS-based factor values were then applied to extract the three compounds 
from spiked water samples and the experimental EF values compared to the 
predicted ones.  
 Method application to human urine 4.10
The method optimized by spiking water samples was then applied on urine 
samples. The purpose at this stage was to do a comparison study of the possibility 
of matrix effects on the EF values and if possible find ways of counteracting such 
effects. Thus matrix-based calibration curves were constructed to address these 
matrix effects.   
59 
 
 Urine collection 4.10.1
A routine void collection technique was done in collecting an early morning 
specimen type of dark yellow urine from a healthy 24 year old male with no prior 
exposure to hallucinogens and/or hallucinogenic mushrooms. Age and sex of the 
choice of individual that supplied the urine sample was random with no particular 
criteria followed except that the individual must have never used or consumed 
hallucinogenic compounds. No incentive was offered and participation during this 
research was on voluntary basis.  
A total of 406 mL of dark yellow urine was completely voided into a 500 mL 
glass container with a lid. The conductance of undiluted urine was 27.95 mS cm
-1
. 
A 50% (v/v) diluted specimen had a conductance of 15.01 mS cm
-1
 while that for 
a 20% (v/v) urine solution was 5.09 mS cm
-1
. Marickar et al. (2010)  has recorded 
a maximum conductance of 33.9 mS cm
-1
 for early morning urine while Kovacs et 
al. (1999) recorded 25 mS cm
-1
 (Kovács et al., 1999; Marickar, 2010). 
 Urine preparation, spiking and extraction of analytes    4.10.2
After setting the extraction samples to pH 4, the conductance was 231 mS cm
-1
.  
Two portions of the urine sample were diluted at 50% (v/v) and 20% (v/v) urine 
into 200 mL beakers using deionized water. Each diluted urine solution was then 
separated into two equal 100 mL volumes.  One of the 100 mL 50% (v/v) urine 
solutions would then be spiked with 200 µL of the 1000 µg mL
-1
 stock solutions 
to produce 2 µg mL
-1 
individual hallucinogen concentrations. Three 10 mL 
volumes of the spiked 50% (v/v) diluted urine sample were then extracted under 
optimized conditions and enrichment factors evaluated. Unspiked portions of the 
50% (v/v) urine samples were also extracted simultaneously with the spiked 
dilution solutions under optimized conditions in order to investigate possibility of 
matrix effects. Like the spiked urine solution, three extractions were done for the 
unspiked. The procedure was repeated with the 20% (v/v) diluted urine sample. 
The potential use of 100 mM and 200 mM HCl as acceptor phases were also 
tested and compared during this stage. The idea was to help decide on risk versus 
efficiency considering that the pH of 200 mM HCl remained outside the column 
60 
 
working range even after dilution for injection.  The unused diluted urine samples, 
both spiked and unspiked were immediately placed in the refrigerator at 4⁰C. 
 Calculating matrix effects 4.10.3
The influence of matrix effects were expressed mathematically as a percentage 
ratio of total peak area of analyte extracted from spiked urine to peak area of 
analyte in the absence of matrix effects. The peak area due to analyte after 
extraction from urine was its peak area contribution to the total peak area and was 
obtained using equation 14. 
Analyte peak area = total peak area – peak area of interfering compound (14)   
The peak area of the interfering compound was obtained from blank urine 
extractions. The percentage matrix effect was calculated as an average of three 
analyte extractions from spiked diluted urine solutions in comparison to the 
average peak area of analyte in absence of matrix. Formula 15 was used. 
% matrix effect 
 = 100 x average total peak area from spiked urine sample        – 100   (15) 
            average peak area of analyte  
A negative value should indicate matrix suppression, while matrix enhancement is 
represented by a positive value. An absence of matrix effects is ideally given by 
zero, a value seldom obtained when extraction is done from biological samples. 
 Constructing matrix-based calibration curves     4.10.4
A matrix-based calibration approach was used in which diluted urine samples 
were spiked with the analytes at different concentration levels and extracting the 
analytes back out. The general matrix-based calibration procedure involved 
preparing six 20% (v/v) diluted urine samples that were spiked in the 0.1 – 10 µg 
mL
-1
 range with TA, MUS and TRP. The six spiked urine solutions had analyte 
concentrations of 0.1 µg mL
-1
, 0.5 µg mL
-1
, 1 µg mL
-1
, 2 µg mL
-1
, 5 µg mL
-1
 and 
10 µg mL
-1
. Each spiked concentration was then extracted using the MUS-based 
universal extraction conditions. The EF values of each analyte over the specific 
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range of spiking concentrations were then plotted against the spiking 
concentrations giving matrix-based calibration curves. The overall enrichment 
factor for each analyte was estimated as an average of EF values at each calibrator 
spiking concentration level. 
 Method validation         4.10.5
Various approaches that include linearity, repeatability and reproducibility, limit 
of detection (LOD) and limit of quantification (LOQ) were used to validate the 
suitability of our developed method for its potential use in quantifying MUS and 
its precursors from urine samples. These characteristics were investigated when 
the method was applied in spiked urine samples. These method validation 
measures were used as a way of determining the method’s ability to maintain the 
extraction process at equilibrium over a wide range of analyte concentrations over 
a period of analyte existence in a sample. 
Linearity was tested as the relationship between the instrument’s response to the 
extracted analyte and the spiking concentration. A blank determination procedure 
was used to estimate the LOD and LOQ for each analyte from the mean of the 
blank and the standard deviation of the blank using equation 9 and equation 10 
respectively. 
The intra-day precisions were investigated by performing three repeat extractions 
simultaneously for every spiked analyte concentration. Standard deviations were 
used for error bars. Reproducibility was assessed by means of inter-day 
extractions. The 2 µg mL
-1 
spiked diluted urine preserved at 4
0
C were extracted 
after a day and results compared statistically with those from the fresh urine 
extractions done the previous day using RSD values. The method was again tested 
on the preserved 2 µg mL
-1 
spiked urine sample after five days. 
Other validation parameters that were considered include selectivity and accuracy, 
robustness, extraction range and system suitability. Since it was impossible to 
completely discriminate our analytes from urine matrices, calculation of matrix 
effects was used to compensate for lack of specificity or selectivity. Accuracy of 
the developed method was reported as the reproducibility of EF values over six 
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spiking concentrations used in constructing matrix-based calibration curves. 
System suitability was limited to an HPLC-UV approach. Method suitability was 
addressed through a comparative summary in which the LOD, LOQ and r² values 
for the developed method were compared to other methods that have been used to 
extract MUS from urine samples. The relevance or acceptability of the EF values 
obtained for the extraction of the three analytes was achieved by comparison with 
EF values of other compounds of similar polarity that have been extracted from 
urine samples using carrier-mediated HF-LPME.   
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5 RESULTS AND DISCUSSION 
 Selection of chromatographic conditions 5.1
Of the seven columns investigated, only the reverse phase phenyl and the HILIC 
were recommended for use in LC separation of tryptamine and phenethylamine 
derived polar alkaloids. Figure 13 shows the chromatograms obtained when the 
reverse phase phenyl, amide and hexylphenyl columns were used for separation of 
six alkaloids.  
 
Figure 13  Retention and separation on three RP-columns at optimized conditions. 
Compounds: (1) Muscimol; (2) Tryptophan; (3) 3,4- Dimethoxyphenethylamine; 
(4) Phenethylamine; (5) Tryptamine; (6) Hordenine; (7) Psilocin. Compound 
numbering was based on descending polarity 
In addition to the investigation parameters considered of greater effect in HILIC 
separations and the recommendations for analyte diluents that are considerably 
close to the mobile phase composition (Buszewski and Noga, 2012; Cheng et al., 
2007; Guo and Gaiki, 2011; Hemström and Irgum, 2006; McCalley, 2010), the 
results of this research showed that better separations can be achieved if the 
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analytes extracted using polar protic extraction solvents are diluted with 
moderately polar aprotic solvents for injection. Water, methanol, acetonitrile and 
tetrahydrofuran were investigated as potential analyte diluents for injection into 
the HPLC system. A comparison of MeCN and THF in Figure 14 showed the 
better separating ability of a buffered MeCN mobile phase on a HILIC column 
when THF was used as the diluent. Decreasing the polarity of an injection solvent 
in HILIC separations was predicted to enhance separation by focussing the 
analytes onto the pseudo-stagnant water layer formed on the surface of the HILIC 
column. Thus, tetrahydrofuran (THF) was recommended where methanol is used 
as an extracting solvent of polar hallucinogenic analytes from biological matrices.  
A HILIC column, its mobile phase composition and THF as an injection diluent 
were adopted for further experiments with muscimol, psilocin, tryptamine and 
tryptophan. Flow rate was set at 0.4 mL minˉ¹ using a mobile phase composition 
of MeCN: Buffer 90:10% (v/v) 10 mM formate. The mechanism of analyte 
separation is the extent of partitioning of the analyte between the pseudo-stagnant 
aqua layer that forms at the surface of the stationary phase and the mobile phase 
as confirmed by McCalley and Neue (2008) and Dinh et al. (2013) (Dinh et al., 
2013; McCalley and Neue, 2008). The result is that retention favours the more 
hydrophilic analytes as confirmed by the elution order in Fig 14. General peak 
broadening was observed for those compounds that retained more as shown by the 
peak for tryptophan, a situation that has been reported before (Chirita et al., 2010; 
McCalley and Neue, 2008).  
 Instrument calibration 5.2
The response results for calibrating the HPLC-UV instrument using analyte 
standard solutions in the 0.5 – 10 µg mL-1 are presented in Table 20. The actual 
calibration curves are presented in Fig A1 – A4. The linearity represented by 
coefficient of determination, R² was good and ranged from 0.9929 to 0.9999. The 
high LOD value for TRP might be related to the observed broadening of its peak.  
 
65 
 
Figure 14  Chromatograms when THF and MeCN were used to dilute the MeOH 
stock solutions for analyte injection. Compounds: (7) Psilocin; (6) Hordenine;   
(5) Tryptamine; (4) Phenethylamine; (3) 3,4-Dimethoxyphenethylamine; (2) 
Tryptophan; (1) Muscimol. Muscimol and psilocin were injected at 1 µg mL
-1 
and 
at 0.5 µg mL
-1 
respectively 
Table 20  Summary of instrument calibration results for the four analytes 
 
Analyte 
 
Calibration equation 
 
R
2 
LOD 
(µg mL
-1
) 
LOQ 
(µg mL
-1
) 
MUS 1052.00162.2  xy  0.9929 0.0237 0.0344 
TRP 2568.4106.3  xy  0.9976 0.1655 0.1671 
TA 0073.4176.24  xy  0.9999 0.0269 0.0401 
PSI 116.28933.9  xy  0.9977 0.1007 0.1419 
  y  is the peak area and x the spiking concentration 
 Screening results 5.3
 Half fractional factorial design for tryptamine 5.3.1
The peak areas obtained from the half fractional factorial design experimental 
results for TA are shown in Table A4. The one way ANOVA results done on peak 
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areas in order to determine if the 32 runs gave similar output results is presented 
in Table A6 and Table 21. The F-observed value in the one-way ANOVA results 
was much greater than the F-critical value and the P-value was less than the set 
0.05 implying that two or more of the peak areas of the 32 runs were different.  
Table 21 One-way ANOVA results for extraction of TA (n=3) 
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 1348860.305 31 43511.623 4492.911 6.52E-96 1.631 
Within 
Groups 619.808 64 9.685    
Total 1349480.113 95     
 
The experimental peak areas were then converted to EF values for TA and the 
results are summarized in Table A5. A Pareto chart of effects, normal plot of 
effects and the main effects plot for averages used to identify those parameters 
having a huge impact on the enrichment factor are shown in Figure 15, Figure 16 
and Figure 17 respectively. The Pareto chart average value for the thirty largest 
factor effects was 29.8. All the factors and factor interaction with histograms 
higher than the average value were considered vital. In the normal plot of effects, 
the significant factors and factor interactions were marked in red. For the main 
effects plot, an average response value was represented as a horizontal line and 
the responses with highest deviation from the average were used to visualize the 
effects.   
All the plots agreed on the enhanced effects due to change in SLM carrier 
composition, AP concentration, extraction time and DP pH. The extraction of 
analytes from the DP is carrier mediated hence the observed highest impact of 
SLM carrier composition. The driving force is also governed by the proton 
difference between the DP and the AP solvents. It is however the AP that provides 
counteracting H
+
 ions. Thus SLM carrier composition, AP HCl concentration, 
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extraction time and DP pH were identified as the significant factors that could 
greatly affect the response output if not monitored. These four factors were then 
taken forward for optimization using response surface designs. 
The Pareto chart and the normal plot of effects further identified the combined 
effects of SLM carrier composition and AP concentration as more vital than 
varying extraction time and DP pH. The AP composition-extraction time, the DP 
pH-SLM carrier composition combined effects were also effective. The combined 
effect of the DP pH and less effective stirring rate and presence of a salt appeared 
to be marginally effective.   
 
 
Figure 15  Pareto chart of factor effects for the extraction of TA (Alpha = 0.05, 
only 30 largest effects shown) 
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Figure 16 Normal plot of factor effects for extraction of TA (Alpha = 0.05, only 
30 largest effects shown) 
 
 
Figure 17 Main factor effects plot for response average during extraction of TA 
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 Half fractional factorial design for muscimol     5.3.2
The procedure described in section 5.3.1 was repeated and the same analysis 
strategies were repeated for identification of essential factors when compounds of 
extreme polarity are to be extracted. The study compound was MUS. The peak 
areas and the variance results are given in Table A7 and Table A8. The single 
factor ANOVA results are summarized in Table 22.  
Table 22 One-way ANOVA results for extraction of MUS (n=3) 
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 3953.554 31 127.534 32.794 2.16E-27 1.6423 
Within Groups 233.339 60 3.889    
Total 4186.892 91         
 
The F-observed and the P-value confirmed that several of peak areas from 32 
experiments were significantly different at 95% confidence interval. The average 
peak areas were then converted to EF values for MUS and the results are 
summarized in Table A9.  The main effects were visually identified using the 
three plots of effects given in Figures 18, 19 and 20.  
The Pareto chart of effects identified stirring rate as the only factor with a 
corrected effect value above average. This was also confirmed in the normal plot 
of effects and by a visual analysis of the main effects plot. The polarity of MUS is 
very high with an X log P3 value of -1.4 and water solubility of 5.67 x 10
5
 mg L
-1
. 
This implied that MUS had a high tendency to remain in solution. Stirring 
increased its kinetic energy and its chances of being at the donor phase-SLM 
interface were increased. This might have explained the observed impact of 
stirring on the output compared to other factors.  
The normal plot of effects identified the negative impact of the donor phase pH-
extraction time interaction. The main effects plot further confirmed the negative 
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effect on the response when the donor phase pH was increased. The pKa value of 
the basic N on MUS is 4.8. This basic N can therefore only carry a positive charge 
as required for effective carrier-aided extraction at pH values below 4.8. Between 
pH 4.8 and pH 7 MUS is in its neutral state. In addition to stirring rate, three other 
factors deemed significant were SLM composition, AP concentration and DP pH. 
These factors were presumed to have the same impact on TRP because of polarity 
similarities between the two compounds. The main factor effects plot showed that 
salt content also had a negative impact on the extraction of MUS. This has also 
been observed by Saaid et al. 2009 (Saaid et al., 2009). The explanation lies on 
the increase in viscosity that restricts transfer of very polar compounds. 
 
 
Figure 18 Pareto chart of factor effects for the extraction of MUS (Alpha = 0.05, 
only 30 largest effects shown)  
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Figure 19 Normal plot of factor effects for the extraction of MUS (Alpha = 0.05, 
only 30 largest effects shown)  
 
 
Figure 20  Main factor effects plot for response average during extraction of MUS 
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 Comparing the current screening results to other related studies 5.3.3
Table 23 shows that the screening results for the current study are comparable 
with fractional factorial screening results for other related compounds. Generally, 
very few studies on LPME have been conducted through multivariate approaches. 
In Table 23 it can be seen that the common factors that have been identified 
through fractional designs include the DP pH, AP concentration, extraction time. 
Some studies where a single analyte with a single pKa value, the DP pH and AP 
concentration were not considered for screening and their levels were set in 
relation to the pKa value. This approach has been used in the extraction of 
tramadol by Ghambarian et al. 2011 during which screening was done on 
extraction time, stirring rate, HF length and salt content only (Ghambarian et al., 
2011) .  Related to this approach were optimization experiments by Lezamiz and 
Jonsson, 2007 where only stirring rate, sample volume and fibre length were 
optimized using a Doehler matrix design (Lezamiz and Jönsson, 2007).  
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Table 23    Comparison of essential factors identified through fractional designs 
Compounds 
(X log P3) 
SLM 
composition 
Factors selected  
as essential 
 
Reference 
MUS (-1.4) 
TRP (-1.1) 
Carrier used DP  pH 
AP concentration 
SLM composition 
Stirring rate 
Current study 
TA (1.6) 
PSI (2.1) 
Carrier used DP  pH 
AP concentration 
SLM composition 
Extraction  time 
Current study 
Propylthiouracil 
(0.8) 
Carrier used DP  pH 
AP concentration 
SLM composition 
Extraction  time 
(Ebrahimzadeh et 
al., 2011) 
Fluoroquinolones 
(-1.1 -  2.9) 
Carrier used DP pH 
AP pH 
Extraction time 
(Payán et al., 
2011a) 
Tramadol (-0.3) No carrier Extraction time 
Stirring rate 
HF length 
(Ghambarian et al., 
2011) 
Dinitrophenols 
(1.4 – 3.6) 
No carrier Stirring rate 
DP volume 
Fibre length 
(Lezamiz and 
Jönsson, 2007) 
dextromethorphan 
(3.4) 
chloropheniramin
e (3.4) 
No carrier DP pH 
AP concentration 
Extraction time 
Salt  content 
 
(Ebrahimzadeh et 
al., 2012) 
acidic 
pharmaceuticals 
No carrier DP pH 
AP pH 
Extraction time 
(Payán et al., 
2010) 
Cannabinoids No carrier Salt content 
DP pH 
Organic phase 
volume 
(Emídio et al., 
2010) 
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 Central composite design results 5.4
 Pairing of factors essential for muscimol  5.4.1
The Pareto chart and the normal plot of standardized effects in Figures 21 and 22 
respectively showed that the DP pH and stirring rate had the greatest magnitude of 
effects effect on the EF values for the extraction of MUS. Thus DP pH and 
stirring rate were paired for further optimizations while AP concentration was 
interrelated with the less important SLM composition. The SLM composition 
standardized effect was lower than the critical standardized effect. Its inclusion in 
the vital factors was based on the researcher’s discretion. DP pH and AP 
concentration are responsible for maintaining a high H
+
 gradient between the 
donor phase and the acceptor phase. A high proton gradient drives the carrier-
aided extraction. Stirring rate is needed to enhance contact between the highly 
polar analyte and the carrier impregnated on the supported liquid membrane.  
When compared to initial screening experiments, the following were further 
observed. A strong effect of AP concentration even though not as strong as DP pH 
and stirring rate and a change in the order of factor effects was observed. During 
screening experiments in which two levels of each factor were investigated, the 
order of effects was stirring rate followed by SLM composition then AP 
concentration and finally DP pH. This changed when five factor levels were 
investigated to DP pH, stirring rate, AP concentration and SLM composition in 
order of descending factor effect. This explains the need for an experimental-
based pairing step before the factors can be optimized. As shown during screening 
designs, the DP pH had a pronounced negative effect. The pH values investigated 
were 3, 4, 5 and 6. The pKa value of MUS at the basic N is 4.8. Above pH 4.8, 
MUS exists in its neutral state. A neutral state of the analyte would result in a 
decrease in carrier mediated extractions.  
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Figure 21 Pareto chart of standardized effects of the main factors of MUS (Alpha 
= 0.05)    
 
Figure 22   Normal plot of standardized effects of the main factors on MUS 
(Alpha = 0.05) 
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 Pairing of factors essential for tryptamine     5.4.2
Based on visual analysis of the Pareto chart (Figure 23) and the normal plot 
(Figure 24) of standardized effects, the effects order was extraction time, AP 
concentration, DP pH and SLM composition. Keeping the analytes at the donor 
phase-SLM interface for a longer time enhances contact with the carrier molecule. 
Increasing the AP concentration helps maintain a higher proton gradient. These 
two factors were therefore observed to have standardized effects above the critical 
standardized value.  The SLM composition had the lowest effect on the response 
output with several interaction effects having a greater impact than this factor.  
Also a change in the effect order was observed compared to screening design 
results.  
 
 
Figure 23  Pareto chart of standardized effects of TA (Alpha = 0.05)  
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Figure 24  Normal plot of standardized effects of main factors on TA (Alpha = 
0.05).  
 Paired factor optimization for muscimol 5.4.3
Unless specified, the conditions were DP pH 5, 100 mM HCl concentration, 15% 
(w/w) DEHPA in DHE and stirring at 800 rpm for 60 mins with no salt added.  
Donor phase pH and stirring rate optimization results for muscimol 
Figures 25 and 26 show a contour plot and a surface plot of effects versus a 
pairing of DP pH and stirring rate. A slightly negative rising ridge pattern was 
observed for both the contour plot and the normal plot. The darkening of the 
contour colours represented an increase in response while the brightening surface 
plot was used to represent increase. The rising ridge pattern implied that increase 
in response was achieved by increasing stirring rate while slightly reducing the 
DP pH. For a constant optimal stirring rate of 800 rpm, setting a pH value below 4 
or towards 5 and above reduced the output response. This could be explained by 
the pKa value of MUS. Cationic MUS can only exist at pH 4.8 and below. 
Increasing stirring rate at pH values less than 4 resulted in a marked increase in 
the response compared to pH values above 5. Below pH 4 there were more 
cationic MUS. While the H
+
 ion gradient between donor phase and acceptor phase 
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is minimal, increasing stirring rate increased the contact of the MUS cations and 
the carrier ions at the donor phase-SLM interface.  
The optimum interrelated factor values were then estimated at the point of 
curvature and identified as DP pH 4 and stirring rate of 900 rpm. These were 
summarized as an optimization plot of factors as shown in Fig 27.  Under these 
conditions the response, y which represented the EF value for the extraction of 
MUS from the spiked water into a 100 mM HCl acceptor phase was 11. The 
desirability of the two optimized factors in maximizing the response was an 
acceptable 0.797. Unlike the DP pH which maximized at pH 4, the stirring rate 
optimization rate showed that better responses could have been found if stirring 
had been done at higher rates. However the stirring rate was set by the researchers 
at 900 rpm. To confirm the predicted EF value, experimentation was done at DP 
pH 4 and 900 rpm stirring rate. 
 
 
Figure 25 Contour plot of EF values of MUS versus the interrelated effect of 
stirring rate and DP pH 
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Figure 26 Surface plot of EF values of MUS versus the interrelated effect of 
stirring rate and DP pH 
 
 
Figure 27  Optimization plot of effects of stirring rate and DP pH on enrichment 
of MUS 
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Acceptor phase concentration and supported liquid membrane composition 
optimization results for muscimol   
 The contour plot (Figure 28) and the normal plot (Figure 29) also showed a rising 
ridge pattern in the response output when the AP concentration and SLM 
composition were interrelated. The two factors had an almost linear correlation on 
the response output. The availability of the carrier molecule at a higher H
+
 ion 
gradient continuously increased the extraction of MUS from the donor phase into 
the acceptor phase. The AP concentration plateaued from 80 mM while the SLM 
composition minimal plateau value was 15% (w/w) DEHPA in DHE. The AP 
concentration upper limit was set at 100 mM HCl as an HPLC system protective 
approach.  
 
 
Figure 28  Contour plot of EF values of MUS versus the interrelated effect of 
SLM composition and AP concentration 
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Figure 29  Surface plot of EF values of MUS versus the interrelated effect of SLM 
composition and AP concentration 
The point of curvature values was identified from the optimization plot in Figure 
30. The optimal AP concentration value was 89 mM HCl while SLM composition 
curved at 18% (w/w) DEHPA in DHE with a predicted EF value of 16. An 
individual desirability value of 0.918 was high enough to accept the optimized 
factor values. For experimental purposes, the AP concentration and SLM 
composition were set at 100 mM HCl and 20% (w/w) respectively. 
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Figure 30  Optimization plot of effects of SLM composition and AP concentration 
on enrichment of MUS 
 Paired factor optimization for tryptophan 5.4.4
TRP has polarity similar to MUS and the paired factors identified for MUS were 
used and optimized for the extraction of TRP. Unless specified, the conditions 
were DP pH 5, 100 mM HCl concentration, 15% (w/w) DEHPA in DHE and 
stirring at 800 rpm for 60 mins with no salt added.  
Donor phase pH and stirring rate optimization results for tryptophan  
The contour plot and the surface plot of the response due to the combined effect 
of stirring rate and DP pH showed a co-related response that is affected more by a 
change in DP pH. Increasing the DP pH at any constant stirring rate greatly 
affected the response as shown by the size of the contours across the pH value 
range in Figure 31 and the surface response in Figure 32. Increasing the stirring 
rate seemed less effective when a DP pH level was kept constant. For example, 
the response remained in the 28 – 32 region when stirring rate was increased from 
600 to 900 rpm while DP pH was kept at 4. The response was greater than 36 for 
DP pH value of above 5 and stirring rate of 700 rpm. Also the graphs showed that 
when DP pH is increased above 5, a similar response can be obtained at lower 
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stirring rates. For example, at DP pH 7, the response remained higher than 36 with 
600 rpm of stirring.  
The optimum factor values were DP pH 7 and a stirring rate of 770 rpm as shown 
in the optimization plot in Figure 33. The stirring rate was identified as the point 
of curvature while the DP pH was limited by the set upper limit value. This value 
was set at pH 7 because of the acidic nature of the carrier molecule. During 
preliminary studies it was discovered that pH values in the basic region resulted in 
reduced response. The desirability value for the interrelated effect of DP pH and 
stirring rate was 0.746. The predicted EF value was 40. This value was tested 
experimentally by setting DP pH and stirring rate at 7 and 800 rpm respectively. 
 
 
Figure 31  Contour plot of EF values of TRP versus the interrelated effect of 
stirring rate and DP pH 
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Figure 32  Surface plot of EF values of TRP versus the interrelated effect of 
stirring rate and DP pH 
 
 
Figure 33  Contour plot of effects of stirring rate and DP pH on enrichment of 
TRP 
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Acceptor phase concentration and supported liquid membrane composition 
optimization results for TRP 
Figure 34 shows a static ridge pattern in the 15 – 20% (w/w) SLM carrier 
composition range. Increasing the AP concentration in this region was more 
effective compared to SLM composition levels outside this ridge range. A change 
in the SLM composition in this region had minimal effect on the response output. 
While increasing SLM composition increases the amount of carrier available for 
extraction, it appeared that the AP concentration was more important in the 
vicinity of the optimum SLM composition. Figure 35 visualizes this observation 
as a surface plot. 
The interrelated optimum conditions are summarised as an optimization plot in 
Figure 36. SLM composition polynomial showed curvature at 20% (w/w) DEHPA 
in DHE. For AP concentration, the set upper level value was identified as the 
optimum value. The optimum value could have been higher if a higher AP 
concentration was used. The desirability of the optimized values of the AP 
concentration-SLM composition paired effect was 0.776 with an expected 
enrichment response of 41. For experimentally, the AP concentration and SLM 
composition were set at 100 mM HCl and 20% (w/w) DEHPA in DHE 
respectively. 
 
86 
 
 
Figure 34  Contour plot of EF values of TRP versus the interrelated effect of SLM 
composition and AP concentration 
 
 
Figure 35  Surface plot of EF values of TRP versus the interrelated effect of SLM 
composition and AP concentration 
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Figure 36  Contour plot of effects of SLM composition and AP concentration on 
enrichment of TRP 
 Paired factor optimization for TA 5.4.5
Unless specified, the conditions were DP pH 5 with 0.001% (w/v) NaCl, 200 mM 
HCl AP, 15% (w/w) DEHPA in DHE at 800 rpm for 60 mins. 
Donor phase pH and acceptor phase concentration for tryptamine 
The contour plot and the surface plot of response versus the combined effect of 
DP pH and AP concentration were given in Figure 37 and Figure 38 respectively. 
A slightly rising ridge surface response pattern was observed at around DP pH 6. 
TA is completely cationic below pH 6.9. The response was affected less by a 
change in AP concentration compared to DP pH levels on either side of the slope 
of the ridge. In the vicinity of the ridge above pH 5, a further increase in the pH 
level had less impact on the response output. The interrelationship between AP 
concentration and DP pH seemed to be dependent on maintaining a high H⁺ ion 
gradient. The ridge pattern showed that high responses were obtained at near 
neutral DP pH levels and higher AP concentration. 
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The optimum values were a DP pH of 6 and AP concentration of 200 mM HCl. 
Figure 39 below showed that the desirability of these two optimum values was 
0.993 with an estimated enrichment of 298. As observed with other pairs that 
involved AP concentration, the optimum value for the AP concentration was 
limited by the set upper limit value. The DP pH value was obtained at the point of 
curvature of the quadratic polynomial. Adopted for extraction of TA was DP pH 6 
and 200 mM HCl as the AP.  
 
 
Figure 37  Contour plot of EF values of TA versus the interrelated effect of AP 
concentration and DP pH 
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Figure 38  Surface plot of EF values of TA versus the interrelated effect of AP 
concentration and DP pH 
 
 
Figure 39  Optimization plot of effects of AP concentration and DP pH on 
enrichment of TA 
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Extraction time and supported liquid membrane composition for tryptamine 
 A clearly defined maximum region of optimum response due to stirring rate-SLM 
composition interaction was observed as seen in Figures 40 and 41.  This area was 
in the 55 – 75 mins extraction time and about 15% (w/w) DEHPA in DHE.  On 
either side of the maximum spot, the response due to simultaneously changing the 
paired factor values was reducing. It was observed that at any SLM composition 
level, increasing extraction time was less important while the opposite was true 
for increasing SLM composition. This observation meant that the amount of 
carrier molecules in the supported liquid membrane in the pores of the hollow 
fibre was more important than the analyte-carrier contact time at the DP-SLM 
interface.   
 
 
Figure 40  Contour plot of EF values of TA versus the interrelated effect of 
extraction time and SLM composition 
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Figure 41  Surface plot of EF values of TA versus the interrelated effect of 
extraction time and SLM composition 
Using a quadratic polynomial, the optimum factor values were 15% (w/w) 
DEHPA in DHE for SLM composition and 66 mins for extraction time. The 
polynomials for both factors had a point of curvature as shown in Fig 42 from 
which the optimum factor values were estimated. The dual desirability was 0.979 
implying that an EF value of 257 achieved under these conditions was favourable 
for the enrichment of TRP.   
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Figure 42  Optimization plot of effects of extraction time and SLM composition 
on enrichment of TA 
 Paired factor optimization for psilocin 5.4.6
PSI has polarity similar to TA and the paired factors identified for TA were used 
and optimized for the extraction of TRP. Unless specified, the conditions were DP 
pH 5 with 0.001% (w/v) NaCl, 200 mM HCl AP, 15% (w/w) DEHPA in DHE at 
800 rpm for 60 mins. 
Extraction time and supported liquid membrane composition for psilocin 
Figure 43 and Figure 44 show an apex region in the vicinity of 70 mins and 20% 
(w/w) DEHPA in DHE. The slope of its sides was non-static with a better 
enhancing response observed when the SLM composition was changed. This 
observation could have meant that the amount of DEHPA embedded on the SLM 
was more important than the extraction time. Increasing extraction time at any 
SLM composition level had very little impact on the response output. 
The reduced slope of the contours in the vicinity of the optimum extraction time 
meant that around the optimum factor levels, the change in the response is 
minimal regardless of whether you are changing the SLM composition or the AP 
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concentration. These results meant that maintaining the amount of the carrier at 
optimal levels was more important than the time the carrier was in contact with 
the analyte. The optimization plot in Figure 45 showed optimum values of 20% 
(w/w) DEHPA in DHE and extracting the analyte for 67 mins. At this stage PSI 
got finished and no further optimization could be done. The dual desirability was 
0.883 producing a predicted EF value of 311. Experimentally, SLM composition 
was set at 20% (w/w) DEHPA in DHE and extraction for 60 mins. 
 
 
Figure 43  Contour plot of EF values of PSI versus the interrelated effect of 
extraction time and SLM composition  
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Figure 44  Surface plot of EF values of PSI versus the interrelated effect of 
extraction time and SLM composition  
 
Figure 45  Optimization plot of effects of extraction time and SLM composition 
on enrichment of PSI 
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 Quadratic response surface models for paired factor optimizations 5.4.7
All the prediction quadratic response surface models used to estimate optimum 
values in plots for each paired factor investigations are shown in Table 24.  The 
models were estimated by quantifying equation 13. The regression coefficients for 
each response model were estimated using uncoded output data in Minitab. 
 Comparison of optimized factor levels in different articles 5.4.8
While the optimum values for DP pH and AP concentration are dependent on the 
physicochemical properties of the analytes under study, the SLM carrier 
composition, stirring rate and extraction time values are expected to be universal 
for a HF-LPME approach. A similar optimum value of 20% (w/w) DEHPA in 
DHE has been reported in other studies (Dziarkowska et al., 2008; Poliwoda et al., 
2010). Romero et al. (2002) found a desirable optimum of 16.5% (w/w) DEHPA 
in DHE for extraction of eight analytes with individual optimum values ranging 
from 13% (w/w) DEHPA in DHE to 22% (w/w) DEHPA in DHE (Romero et al., 
2002). Yamini et al. (2006) optimized the  Aliquot 336  content in n-octanol at 
20% (w/w) (Yamini et al., 2006). Table 25 shows factor values that are closely 
related to optimum values from this study. However some extreme factor values 
like 1600 rpm for 30 mins (Saaid et al., 2009), 2200 rpm for 2 h (Van Pinxteren et 
al., 2012), 300 rpm for 6 h (Payán et al., 2011b) and 900 rpm for 4 h (Hyder and 
Jönsson, 2012) have been reported.   
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Table 24 Summary of quadratic response surface models for two factor interactions using uncoded data.  
 Paired factors Predictive quadratic response models for paired factor optimizations during individual analyte extractions 
 
 
MUS 
DP pH and  
stirring rate 
))((00375.0)(10732.1)(129.2)(0585.0)(200.21565.65 252 RateDPpHRateDPpHRateDPpHy    
AP concentration 
and SLM 
composition 
))((00377.0)(0599.0)(00354.0)(821.1)(564.0875.25 22 SLMcompoAPconcSLMcompoAPconcSLMcompoAPconcy   
 
 
 
TRP 
 
DP pH and  
extraction rate 
 
))((0001.0)(0001.0)(732.0)(1984.0)(764.10334.76 22 RateDPpHRateDPpHRateDPpHy   
AP concentration 
and SLM 
composition 
 
))((00726.0)(0796.0)(10022.8)(472.2)(0496.0177.3 225 SLMcompoAPconcSLMcompoAPconcSLMcompoAPconcy  
 
 
 
TA 
DP pH and  
AP concentration 
))((0955.0)(840.5)(360.14)(524.0)(371.163140.363 22 APconcDPpHAPconcDPpHAPconcDPpHy   
SLM composition 
and extraction time 
 
))((0409.0)(0487.0)(716.1)(038.7)(556.54551.387 22 TimeSLMcompoTimeSLMcompoTimeSLMcompoy   
PSI SLM composition 
and extraction time 
))((265.0)(148.0)(411.0)(729.14)(528.8116.360 22 TimeSLMcompoTimeSLMcompoTimeSLMcompoy   
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Table 25   Summary of optimum levels for non-analyte related factors  
Stirring rate 
(rpm) 
Extraction time 
(mins) 
 
Reference 
800 60 (Current study) 
800 60 (Yang et al., 2010) 
1000 80 (Hadjmohammadi and 
Ghambari, 2012) 
600 60 (Han and Row, 2010) 
660 90 (Lezamiz et al., 2008) 
750 50 (Miraee et al., 2014) 
900 60 (Xiao-Wang et al., 2012) 
600 50 (Yamini et al., 2006) 
 
 Comparison of predicted EF values with experimental values for 5.5
individual extractions under specific optimum values 
When each analyte was extracted individually, the experimental EF values were 
above the predicted EF range as shown in Table 26 except for MUS. The range 
for MUS was obtained in the absence of salt. The expected EF values were given 
as a range because each pair of factors gave its own response. The peak areas 
obtained through experimentation are shown in Table A5.  
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Table 26 Experimental versus Minitab 16-predicted EF values under optimum 
conditions for extracting TA, MUS and TRP individually. 
 TA MUS TRP PSI 
SLM composition (% w/w) 15 20 20 20 
DP pH 6 4 7 5 
AP concentration  (mM HCl) 200 100 100 200 
Extraction time (mins) 60 60 60 60 
Stirring Rate (rpm) 800 900 800 800 
NaCl composition (% w/v) 0.001 0.001 0.001 0.001 
Expected EF 257 - 298 11 - 16 40 - 41 311 
Experimental EF values 316 11 45 - 
%RSD 4.24 10.01 1.75 - 
 
 Comparison of predicted EF values versus experimental values for 5.6
simultaneous extractions under conditions optimized for muscimol 
 Changes in predicted EF values and individual desirabilities  5.6.1
Figures 46 - 50 show the changes in individual desirabilities and predicted EF 
values when the optimized conditions for MUS were set for a simultaneous 
extraction of all the analytes.  Only the stirring rate was changed to 800 rpm. A 
general decrease in EF values and individual desirabilities was observed. Most 
affected was extraction of TA especially the desirability of setting DP pH and AP 
concentration to 4 and 100 mM HCl respectively. A desirability of 0.448 was 
considered unsuitable but was accepted in this case because the developed method 
targeted maximizing the primary analyte, MUS.  An individual desirability of 
0.448 for TA still predicted an EF value of 145.  
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Figure 46  Effects of setting the stirring rate to 800 rpm on the desirability and 
response output for MUS 
 
 
Figure 47  Effects of setting MUS-based levels of DP pH and stirring rate on the 
dual desirability and response output for TRP 
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Figure 48  Effects of setting MUS-based levels of AP concentration and SLM 
composition on the dual desirability and response output for TRP 
 
Figure 49  Effects of setting MUS-based levels of DP pH and AP concentration on 
the dual desirability and response output for TA 
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Figure 50  Effects of setting MUS-based levels of SLM composition and 
extraction time on the dual desirability and response output for TA 
 Compound desirability  5.6.2
The compound desirability, D of setting MUS optimum conditions as universal 
factor levels for a simultaneous extraction of MUS, TRP and TA was finally done 
by substituting for m  in equation 5 to form equation 15.  
6/1
665544332211 ).....( ydydydydydydD       (15) 
6/1)81461.044768.085693.053154.088268.071423.0(   
= 0.68655 
A D-value of 0.687 implied that the set conditions were ideal for a simultaneous 
extraction of the analytes from the donor phase into the acceptor phase across a 
supported liquid membrane impregnated with a carrier molecule. This was a fair 
result considering that only one of the responses was used to set the factor values. 
A different value could have been obtained if the purpose was to maximize EF 
values for all analytes.  
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When the three analytes were finally extracted simultaneously under the MUS-
biased conditions, only the experimental EF value for TRP was within the 
predicted range as shown in Table 27. Most affected was the most polar MUS 
which dropped by 40% below the minimal experimental value. The percentage 
difference was calculated using equation 16. 
100/)( )(minexp)(min  imumpredictederimentaimumpredicted EFEFEFDifference     (16) 
Table 27 Comparison of predicted and experimental EF values when TA, MUS 
and TRP were extracted simultaneously under universal factor levels  
 TA MUS TRP PSI 
Expected EF 145 - 215 10 - 15 31 - 41 ND 
ND Experimental EF 140 6 33 
RSD 0.0251 0.0220 0.0167 - 
Conditions: DP pH 4 with 0.001% (w/v) NaCl, 100 mM HCl AP, 20% (w/w) 
DEHPA in DHE and stirring at 800 rpm for 60 mins. ND – Not detected.  
The experimental EF values were expected to be higher than the predicted range. 
The observed experimental EF values compared to predicted values might be that 
predictions from Minitab disregarded possibility of competition in binding to the 
carrier molecule. A reduction in the EF value for the extremely polar MUS was 
expected considering that mixing analytes in a single donor phase might result in 
analytes competing for the carrier molecule during extraction. During screening 
experiments, an increase in NaCl content in the DP reduced extraction of MUS. 
Thus the 10 – 15 predicted range was obtained in the absence of salt in the DP. 
The EF values in Table 28 were obtained when the AP concentration was 
increased from 100 mM to 200 mM HCl. Increasing the AP concentration was 
most effective for the enrichment of the least polar TA with a 49% increase while 
it was less for the polar MUS and TRP. Enrichment of MUS increased by 33% 
and TRP increased by 9%. During screening experiments it was shown that AP 
concentration is not so effective in the extraction of polar analytes.  
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Table 28 EF values for simultaneous extraction of TA, MUS and TRP using 200 
mM HCl as the acceptor phase (n=3). 
 TA MUS TRP 
Average EF value 208 8 36 
SD 4.0161 0.3771 2.1524 
RSD 0.0193 0.0464 0.0596 
%RSD 1.93 4.64 5.96 
 
 Applying the method in urine samples 5.7
 Spiked urine extraction results  5.7.1
A visual comparison of chromatograms from blank and spiked urine extractions in 
Figure 51 showed presence of co-extracted compounds some of which co-eluted 
with our analytes of interest. Most affected was MUS. A big peak was observed 
that eluted within 0.01 mins of MUS elution. This peak could not be separated 
from the MUS peak even when elution was done at 0.2 mL min
-1
. Deja et al. 
(2014) identify urea as the interfering compound responsible for this peak (Deja et 
al., 2014).  The same was observed with interference on the TRP peak. While the 
TA peak was prominent at 1.19 ± 0.01 mins, there were two peaks that eluted at 
1.10 mins and at 1.49 mins. The 1.10 mins elution time peak could not be baseline 
separated from the TA peak. The peaks for blank extraction chromatograms were 
considered to be representative of matrix effects.  
Chromatograms marked (b) in Figure 51 were obtained by injecting the AP 
diluted six-fold and was used to quantify MUS and TRP. The AP was diluted 53-
fold for chromatograms marked (a) and were used to quantify TA. Compared to 
the retention times obtained during column selection experiments (Figure 14), it 
was observed that there was a general decrease in retention of analytes. This was 
attributed to the amount of THF used for diluting the AP before injection into the 
HPLC system. During HILIC column optimization, dilution was up to 2000 times 
and the analytes were retained more in the column. The effect of the THF diluent 
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amount is also apparent for the 6-fold and the 53-fold dilution chromatograms. 
This observation further enhances the findings of this research that use of a 
relatively non-polar diluent is essential for retention and hence effective 
separation of polar compounds as given in section 5.1.  
 
  
Figure 51  Comparison of blank urine peaks and the 2 µg mL-1 spiked urine peaks 
for the extraction of TA (a) and, MUS and TRP (b) 
Analytes extracted from a 20% (v/v) diluted urine sample using 200 mM HCl as 
the acceptor phase gave better peak areas of analytes compared to when either 100 
mM HCl was used and also to when the analytes were extracted from a 50% (v/v) 
diluted urine solution. For MUS, it was observed that extraction was near 
impossible when urine was diluted at 50% (v/v). Table 29 is a comparison of peak 
areas for MUS obtained from blank and spiked urine extractions. The same was 
observed when 100 mM HCl was used with the peak of the interfering compound 
contributing 29.021 ± 0.0417 in a total spiked extraction peak area of 29.022 ± 
0.007 (n=3, RSD). Thus further studies were carried on 20% (v/v) deionized 
water-diluted urine samples which equated to a dilution ratio of 1:4.  
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Table 29 Average peak areas for extraction of MUS from 2 µg mL
-1 
spiked diluted 
urine solutions using 200 mM HCl as acceptor phase (n=3) 
 Blank extraction Spiked extraction Peak area for MUS 
Urine dilution  50% (v/v) 20% (v/v) 50% (v/v) 20% (v/v) 50% (v/v) 20% (v/v) 
Peak area 57.472 23.386 57.502 26.251 0.03 2.864 
SD 0.3883 0.0100 0.0058 0.4596 0.0058 0.1255 
RSD 0.0068 4.3E-04 1E-04 0.0175 0.1917 0.0438 
%RSD 0.65 0.04 0.01 1.75 19.17 4.38 
 
Generally there was a marked reduction in EF values for the three analytes when 
they were extracted from urine compared to when extracted from deionized water 
samples. Table 30 compares the EF values when 200 mM HCl was used to extract 
the analytes from water and from urine samples.  The observed reduction in EF 
values for the three analytes was confirmation of the complexity of urine 
specimens and the matrix effect challenges associated with urinalysis. The hollow 
fibre is a size exclusion separation technique and therefore any low molecular 
weight compound would be expected to be found at the donor phase-SLM 
interface. This would reduce the surface area for analyte interaction with the 
carrier molecule. The anionic nature of the carrier molecule indicates selectivity 
for any positively charged component of urine like metallic cations, urea and 
creatinine. Similar scenario has been observed in most urinalysis chromatographic 
separation and quantification (Dziarkowska et al., 2008; Yamini et al., 2006). It 
should be noted that dark yellow urine was targeted in this investigation so as to 
maximize the matrix effects during method development. An average urine colour 
of a healthy person would be light yellow.  
 Calculating matrix effects 5.7.2
The extent of matrix effects when the method was applied on spiked 20% (v/v) 
diluted urine is given in Table 31. Equation 13 and 14 were used. The peak area 
that interfered with the MUS was extremely enhancing with a positive percentage 
matrix effect value of 840. This implied that the optimized conditions might have 
favoured the interfering compound however this could not be ascertained. 
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Surprisingly TA which experienced minimal matrix effects with a value of 3.4 
had the highest percentage EF reduction as shown by the summary of percentage 
EF value reductions when extractions were done from 2 µg mL
-1 
spiked urine 
using 200 mM HCl as the acceptor phase in Table 32. TRP with a median value 
for matrix effects experienced the least reduction in its EF value. 
 
Table 30 Comparison of EF values of TA, MUS and TRP in water and diluted 
urine samples spiked at 2 µg mL
-1 
(n=3) 
 TA MUS TRP 
 Water 20% (v/v) Water 20% (v/v) Water 20% (v/v) 
EF 208.4 25.5 8.4 4.2 36.1 21.6 
SD 4.016 0.602 0.074 0.684 2.152 2.438 
RSD 0.019 0.024 0.009 0.161 0.060 0.113 
%RSD 1.9 2.4 0.9 16.1 6.0 11.3 
 
Table 31 Percentage matrix effects on extraction of TA, MUS and TRP from a 2 
µg mL
-1 
spiked diluted urine sample using 200 mM HCl as the acceptor phase 
(n=3, RSD)  
 TA MUS TRP 
 20% v/v 20% v/v 20% v/v 
Total peak area 24.037 ± 0.0228 26.251 ± 0.0176 29.962 ± 0.0817  
Interfering compound  0.706 ± 0.0234 23.386 ±0.0004 9.028 ± 0.0004 
Analyte peak area 23.331 ± 0.0235 2.864 ± 0.1605 20.934 ± 0.1169 
% matrix effect 3.026 ± 0.0235 840.331± 0.1773 43.773  ± 0.1269 
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Table 32 Summary of percentage reductions in EF values when TA, MUS and 
TRP were extracted from spiked diluted urine compared to spiked water samples  
 TA MUS TRP 
EF value  from water 208.4 8.1 36.1 
EF value from urine 25.5 4.2 21.6 
% EF reduction 87.7 48.1 40.1 
  
It was observed that the extent of matrix effects as shown in Table 33 was higher 
when the urine was less diluted and this was also observed when a more 
concentrated HCl acceptor phase was used. For a less diluted urine sample, the 
interfering compounds still exist in higher concentrations while a higher 
concentration of the acceptor phase maintains a high proton gradient essential for 
effective extraction of any cationic compound.  However, the enrichment factor 
values showed that the use of a stronger HCl acceptor phase was more important 
than diluting the sample especially with TA and TRP. This could be attributed to 
the increased H⁺ ion gradient which is actually the driving force in carrier 
mediated hollow fibre extraction.  
 
Table 33 Comparison of matrix peak areas in EF values for TA, MUS and TRP in 
spiked diluted urine samples 
HCl  TA MUS TRP 
(mM)  50%  20% 50% 20% 50% 20% 
 
100 
Matrix         
peak area 
 
1.04 
 
0.319 
 
29.0 
 
21.9 
 
13.5 
 
5.0 
EF value 5.5 10.1 ND* 1.5 14.3 16.7 
 
200 
Matrix        
peak area 
 
2.55 
 
0.706 
 
57.5 
 
23.4 
 
27.6 
 
9.0 
EF value 12.2 25.5 0.02 4.2 17.5 21.6 
  ND - Not detected  
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For MUS where diluting the urine sample seemed to be more effective, the 
explanation might lie in the extent of extraction of the interfering compound.  The 
peak of the interfering compound was at least 99.9% of the total peak area for a 
50% (v/v) dilution urine solution and between 95.3 – 96.4% for a 20% (v/v) urine 
solution. Diluting the urine helped by diluting the interfering compound thus 
allowing an increase in the extent of extraction of MUS. This observation also 
concurs with the observations made during optimization experiments where 
stirring rate was more important than AP concentration during extraction of more 
polar compounds. Muscimol is the most polar analyte in our study and diluting 
the interfering compound allows MUS to have more contact with the hollow fibre 
at the DP-SLM interface. For TA, the maximum percentage contribution of matrix 
effect to the total peak area was 18.7% where the urine had been diluted at 50% 
(v/v) and 200 mM HCl used as the acceptor phase. The maximum contribution 
due to matrix effects on TRP was 62.2% at the same extraction conditions. These 
percentage values due to matrix effects were considered very high and hence the 
decision to correct for the matrix effects using a matrix-based calibrator. 
Having identified diluting the urine samples at 1:4 giving a urine solution of 20% 
(v/v) using 200 mM HCl as the acceptor phase as the minimal conditions that 
allow for effective enrichment of our analytes at a spiked concentration of 2 µg 
mL
-1
, the next step was to construct a matrix-based calibration curve for each 
analyte.   
 Matrix-based calibration curve for tryptamine 5.7.3
Table 34 shows the average peak areas and EF values when  TA was extracted 
from 20% (v/v) diluted urine solutions spiked at 0.1 µg mL
-1
, 0.5 µg mL
-1
, 1 µg 
mL
-1
, 2 µg mL
-1
, 5 µg mL
-1
 and 10 µg mL
-1
 using 200 mM HCl as an acceptor 
phase.   
A matrix-based calibration was then constructed as a plot of spiking concentration 
versus average peak area and is given in Figure 52. Average total peak areas 
obtained by diluting the AP with 20 µL of acetonitrile and 500 µL of THF were 
used. For example, for a 10 µg mL
-1
 spiked solution in Table 34, the peak area 
used for the calibration curve was 104.252. The peak area of the interfering 
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compound was included in the residual points as the response when the analyte 
spiking concentration was 0 µg mL
-1
. This point was also set as the y-intercept of 
the calibration curve. The manipulated regression line had an r² value of 0.9986 
while a true regression line had an R² value of 0.9991. 
Another calibration curve was plotted in which the final total peak areas assuming 
the AP phase was not diluted were used. In this case, the 104.252 peak area was 
multiplied by the dilution factor, 53 to obtain 5525.363. This value was then used 
for the calibration curve in Figure 53. The same was done with peak areas of other 
spiked concentration levels. Whether the calibration curve in Figure 52 or Figure 
53 was used to predict concentration from a peak area, the result was the same. 
However the choice of Figure 52-type of calibration curve where the peak areas 
due to dilution of the acceptor phase were used allow for flexibility in terms of the 
extent of dilution. A dilution mistake made during analysis will not affect the 
outcome while a Figure 53-type approach is not flexible in that regard. Thus a 
matrix-based calibration curve plotted using the peak areas of diluted acceptor 
phase is recommended. 
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Table 34 Summary of data for calculating EF values for extracting TA from six different spiking concentrations (n=3, RSD) 
Spiking 
concentration 
(µg mL
-1
) 
Average 
total peak 
area 
Average  
interfering 
peak area 
Average 
corrected 
peak area 
 
Regression line 
Dilution 
factor 
Average final 
concentration 
(µg mL
-1
) 
Average 
EF value 
0.1 1.731 
± 0.0485 
0.706 
± 0.0266 
1.025 
± 0.0820 
 53 2.05 
± 0.089 
20.81 
±0.088 
0.5 7.185 
± 0.0206 
0.706 
± 0.0266 
6.479 
±0.0229 
 53 14.039 
±0.0231 
28.08 
±0.023 
1 12.393 
±0.0987 
0.706 
± 0.0266 
11.687 
±0.1047 
 53 25.455 
±0.1054 
25.46 
±0.105 
2 24.037 
±0.0228 
0.706 
± 0.0266 
23.331 
±0.0235 
0073.4176.24  xy  53 50.982 
±0.0236 
25.49 
±0.024 
5 51.352 
±0.0803 
0.706 
± 0.0266 
50.646 
±0.0814 
  53 110.863 
±0.0815 
22.68 
±0.081 
10 104.252 
±0.0990 
0.706 
± 0.0266 
103.546 
±0.0997 
 53 226.835 
±0.0997 
22.68 
±0.100 
        y  is the peak area and x is analyte concentration in µg mL
-1
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Figure 52  Matrix-based calibration curve for the extraction of TA from diluted 
urine samples; acceptor phase had been diluted 53 fold. (n=3, SD) 
 
 
Figure 53  Matrix-based calibration curve for the extraction of TA from diluted 
urine samples assuming the AP was not diluted. (n=3, SD) 
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 Matrix-based calibration curve for muscimol 5.7.4
When the diluted urine solution was spiked at 0.1 µg mL
-1
, MUS could not be 
significantly enriched into the acceptor phase. Using single factor ANOVA it was 
shown that there was no significant difference between the blank and the 0.1 µg 
mL
-1
 spiked results as shown in Table 35.  
Table 35 Single Factor ANOVA for blank and 0.1 µg mL
-1
 spiked results.  
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 0.5040 1 0.5040 1.087 0.3561 7.709 
Within Groups 1.856 4 0.4639 
   Total 2.360 5      
 
The F value was less than the F critical value and the P-value greater the set P = 
0.05 value implying that there was no significant difference between the means of 
peak areas for the blank and the 0.1 µg mL
-1
 spiked result. Therefore MUS could 
not be sufficiently enriched into the acceptor phase when it was 0.1 µg mL
-1
 of the 
matrix. 
Table 36 shows the average peak areas and the EF values for MUS obtained when 
the 20% (v/v) diluted urine solution was spiked at 0.5 µg mL
-1
, 1 µg mL
-1
,  2 µg 
mL
-1
, 5 µg mL
-1
  and 10 µg mL
-1
  respectively.  
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Table 36   Summary of data for calculating EF values for extracting MUS from six different spiking concentrations (n=3, RSD) 
Spiking 
concentration 
(µg mL
-1
) 
Average 
total peak 
area 
Average  
interfering 
peak area 
Average 
corrected 
peak area 
 
Regression line 
 
Dilution 
factor 
Average final 
concentration 
 (µg mL
-1
) 
 
Average EF 
value 
0.5 23.851 
± 0.0052 
23.386 
± 0.0004 
0.465 
±0.2690 
 6 1.331 
±0.2796 
3.62 
±0.409 
 
1 24.734 
±0.0062 
23.386 
± 0.0004 
1.348 
±0.1142 
 6 3.958 
±0.1158 
3.96 
±0.116 
 
2 26.251 
±0.0175 
23.386 
± 0.0004 
2.864 
±0.1605 
1052.00162.2  xy  6 8.472 
±0.1615 
4.24 
±0.161 
 
5 30.736 
±0.0170 
23.386 
± 0.0004 
7.350 
±0.0597 
 6 21.820 
±0.0599 
4.36 
±0.060 
 
10 35.483 
±0.0170 
23.386 
± 0.0004 
12.096 
±0.0499 
 6 35.945 
±0.0500 
3.59 
±0.050 
             y  is the peak area and x is analyte concentration in µg mL
-1
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A matrix-based calibration curve for the extraction of MUS from diluted urine is 
given in Figure 54.  The peak area of the 10 µg mL
-1
 spiked concentration was 
excluded from the calibration curve because it seemed to cause a deviation from 
linearity leading to an r² value of 0.9868 compared to r
2
 value of 0.9975 as shown 
in Figure A1. The deviation from linearity due to the 10 µg mL
-1
 spiked 
concentrations might have implied the beginning of a new linear region. However 
this was not confirmed. The peak area of the interfering compound was included 
in the residual points as the response when the analyte spiking concentration was 
0 µg mL
-1
. This point was also set as the y-intercept of the calibration curve. The 
manipulated regression line had an r² value of 0.9975 while a true regression line 
had an R² value of 0.9996.  
 
 
Figure 54  Matrix-based calibration curve for the extraction of MUS from diluted 
urine samples spiked up to a concentration of 5 µg mL
-1
. The acceptor phase had 
been diluted 6 fold. (n=3; SD) 
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 Matrix-based calibration curve for tryptophan 5.7.5
The response for extraction from the 0.1 µg mL
-1
 spiked sample had an RSD of 
85% and the single factor ANOVA in Table 37 proved that there was no 
difference between the blank and the 0.1 µg mL
-1
 peak areas. The 0.1 µg mL
-1
 
results were therefore excluded from calculation of the EF value and the 
construction of the matrix-based calibration curve. Table 38 shows the peak areas 
and EF values for TRP obtained when the 20% (v/v) diluted urine solution was 
spiked at 0.1 µg mL
-1
, 1 µg mL
-1
, 2 µg mL
-1
, 5 µg mL
-1
 and 10 µg mL
-1
. 
A matrix-based calibration curve for the extraction of TRP from diluted urine is 
given in Figure 55. The peak area of the interfering compound was included in the 
residual points as the response when the analyte spiking concentration was 0 µg 
mL
-1
.  
However when this point was set as the y-intercept of the calibration curve, it led 
to LOD and LOQ values of 0.18 µg mL
-1
 and 0.61 µg mL
-1
 respectively. This 
might have been due to bias towards false positives considering that 0.5 µg mL
-1
 
was one of the calibrators. Thus an unaltered regression equation was used for 
TRP.   
Table 37    Single Factor ANOVA for blank and 0.1 µg mL
-1
 spiked result.  
Source of 
Variation SS df MS F P-value F crit 
Between 
Groups 2.516 1 2.516 1.056 0.3622 7.709 
Within Groups 9.529 4 2.382 
   Total 12.044 5      
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Table 38   Summary of data for calculating EF values for extracting TA from six different spiking concentrations (n=3, RSD) 
Spiking 
concentration 
(µg mL
-1
) 
Average 
total peak 
area 
Average  
interfering 
peak area 
Average 
corrected 
peak area 
 
Regression line 
 
Dilution 
factor 
Average final 
concentration   
(µg mL
-1
) 
 
Average 
EF value 
0.5 13.096 
± 0.0471 
9.028 
± 0.0541 
4.068 
±0.1517 
 6 9.522 
±0.1291 
19.04 
±0.129 
 
1 21.088 
±0.0486 
9.028 
± 0.0541 
12.060 
±0..0849 
 6 25.449 
±0.0802 
25.45 
±0.080 
 
2 29.962 
±0..0817 
9.028 
± 0.0541 
20.934 
±0.1169 
2568.41063.3  xy  6 43.135 
±0.1131 
21.57 
±0.1131 
 
5 48.677 
±0.0268 
9.028 
± 0.0541 
38.901 
±0.0386 
 6 78.942 
±0.0379 
16.09 
±0.032 
 
10 89.283 
±0.0904 
9.028 
± 0.0541 
80.255 
±0.1006 
 6 161.359 
±0.0997 
16.14 
±0.0997 
       y  is the peak area and x is analyte concentration in µg mL
-1
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Figure 55  Matrix-based calibration curve for the extraction of TRP from diluted 
urine samples spiked up to a concentration of 10 µg mL
-1
. The acceptor phase had 
been diluted 6 fold. 
 Differences in peak area errors and EF value errors at each analyte 5.7.6
spiking level 
A closer look at the peak errors for three extractions per spiked concentration in 
Table 39 revealed that the results could be relied on with %RSD values ranging 
from 0.5% for extracting MUS from a 0.5 µg mL
-1 
spiked urine solution to 9.90% 
when TA was enriched from a 10 µg mL
-1
 spiked urine diluted sample. However 
in all extractions, the corresponding EF error values were higher than the peak 
area errors.  
The extent of increase in the %RSD error value from peak area errors to EF value 
errors was reducing as concentration of the spiked solution was increasing. The 
most affected was MUS extraction with the EF value error going up to 40.9% 
when MUS was being extracted from a 0.5 µg mL
-1
 spiked concentration. The 
most appropriate explanation might be carry-over effects or propagation of errors 
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during calculations. The low error values for peak areas is because these were 
obtained from raw data from the injection results while several calculation steps 
had to be followed until the EF value was obtained. Also dealing with AP 
volumes in the micro scale and small values of peak areas and later multiplying 
with larger dilution factors might have contributed to enhanced EF value errors. 
However the overall errors in the EF value for each analyte given as RSD were 
acceptable and ranged from 8.3% for MUS to 13.1% for TRP.  
 EF values for the simultaneous extractions from diluted urine samples  5.8
The overall enrichments for the simultaneous extraction of MUS, TRP and TA 
using the developed HF-LPME approach under MUS-based universal factor 
levels are summarized in Table 40. The conditions of extraction were DP pH 4, 
200 mM HCl as the AP, 20 %w/w DEHPA in DHE, 800 rpm stirring rate and 60 
mins extraction time. Equation 17 was used.   
Overall EF value for analyte        
  = (sum of EF – number of spiking concentration)  ±RSD     (17) 
The relatively low EF value for MUS might be related to its polarity and pKa 
values. MUS is highly polar and exists in its neutral state between pH 4.8 and 8.4. 
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Table 39 Summary of errors when three extractions were performed per analyte spiked concentration (n=3). 
Analyte spiked 
concentration 
(µg mL
-1
) 
TA MUS TRP 
Peak area error 
(%RSD) 
EF value error 
(%RSD) 
Peak area error 
(%RSD) 
EF value error 
(%RSD) 
Peak area error 
(%RSD) 
EF value error 
(%RSD) 
0.1 4.9 8.8 - - - - 
0.5 2.1 2.3 0.5 40.9 4.7 12.9 
1 9.9 10.5 0.6 11.6 4.9 8.0 
2 2.3 2.4 1.8 16.1 8.2 11.3 
5 8.0 8.1 1.4 6.0 2.7 3.2 
10 9.90 9.97 1.7 5.0 9.04 9.97 
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Table 40 Summary of EF values for the simultaneous extraction of MUS, TRP 
and TA from diluted urine sample spiked in the 0.1 – 10 µg mL-1.  
Analyte Overall EF value RSD (%) 
MUS 4.1 8.3 
TRP 19.7 13.1 
TA 24.1 10.2 
 
 Method validation 5.9
Table 41 shows that our linear regression prediction model could be relied on for 
the quantification of MUS, TRP and TA from urine samples with r² values 
ranging from 0.9933 for the TRP regression to 0.9986 for the least polar TA. 
These numeric linear association parameters from the matrix-based extractions 
were directly linked to the reproducibility of the EF values over a wide range of 
analyte concentration calibrators. The %RSD values for the overall EF values of 
each analyte after doing extraction from six different spiked urine samples ranged 
from 8.3% to 13.1%. This was satisfactory considering that the overall EF values 
were determined in the 0.1 – 10 µg mL-1 using six spiking concentrations.
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Table 41  Summary of method validation parameters.  
 Matrix based 
regression equation 
 
r² 
 
LOD
 
 
LOQ
 
 
EF 
 
SD 
 
RSD 
 
%RSD 
MUS 386.234565.1  xy  0.9975 0.021 0.069 4.06 0.337 0.083 8.3 
TRP 967.107939.7  xy  0.9933 -0.061 0.38 19.66 2.572 0.131 13.1 
TA   706.033.10  xy  0.9986 0.005 0.018 24.12 2.453 0.102 10.2 
y  is the peak area and x is analyte spiking concentration in µg mL
-1
 
Table 42 Comparison of r² values, LODs and LOQs for the matrix-based calibration and the standard solution-based calibration. 
r² LOD LOQ Type of 
Calibration curve TA MUS TRP TA MUS TRP TA MUS TRP 
0.9994 0.9868 0.9933 0.005 0.021 0.061 0.018 0.069 0.38 Matrix-based 
0.9999 0.9929 0.9976 0.027 0.024 0.166 0.040 0.034 0.167 Standard-based 
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 Limits of detection and quantification  5.9.1
Because blank determination is an interference-based analyte detection technique, 
the average peak areas of the interfering compounds were used in the calculation 
of LOD and LOQ. Equations 18 and 19 were used for LOD and LOQ 
respectively. The matrix-based linear regression equation for each analyte was 
then used to quantify LOD as a minimum quantifiable analyte concentration. 
LOD (peak area) = average peak area of interfering compound + 3SD  (18) 
LOQ (peak area) = average peak area of interfering compound + 10SD  (19) 
One of the major disadvantages of the method-based approach is its inability to 
identify if the measured detection limit is biased towards a false negative or a 
false positive. Ripp 1996 observes that false negatives are a common feature in 
method detection limits (Ripp, 1996). TA which was least affected by matrix 
effects had the lowest detection and quantification limits compared to MUS and 
TRP. This could not be declared as the explanation to the observed scenario as TA 
was also the least polar of the three analytes.  
While standard solution calibration curves gave better linearity, the matrix-based 
calibration curves presented better LOD and LOQ values as shown in Table 42. In 
the matrix-based calibration curves the baseline noise peak had already been 
accounted for in the peak of the interfering compound. The larger LOQ values for 
MUS and TRP might be due to the larger matrix effect contribution to the total 
peak areas.  
 Repeatability and reproducibility  5.9.2
All intra-day experiments were carried out in triplicate and repeatability expressed 
using RSD values. Table 43 shows the RSD values when diluted urine spiked at 2 
µg mL
-1
 preserved at 4
0
C was extracted after a day and results compared 
statistically with those from the fresh urine extractions done the previous day 
using RSD values.  
 
123 
 
Table 43 Reproducibility of EF values of TA, MUS and TRP extracted from the 2 
µg mLˉ¹ spiked urine solution after 24 hrs.  
 TA MUS TRP 
 Peak 
areas 
EF value Peak 
areas 
EF value Peak 
areas 
EF value 
Day 1 24.037 25.49 26.251 4.24 29.962 21.57 
Day 2 21.612 22.83 22.680 -1.08 23.688 15.31 
Average 22.824 24.16 24.465 1.579 26.825 18.44 
SD 1.2125 1.329 1.785 2.657 3.1369 3.1258 
RSD 0.0531 0.0550 0.0730 1.682 0.1169 0.1695 
%RSD 5.31 5.50 7.30 168.2 11.69 16.95 
 
A general decrease in the peak areas was observed even though the %RSD values 
for the average peak area was within acceptable values of 5.31% for the TA peak 
area to 11.69% for the TRP. This observation might be attributed to possibility of 
loss of analyte or even the interfering compounds through some biological 
processes. The stability of our analytes and the interfering compounds in urine 
preserved at 4
0
C was unknown. When the average peak areas for day 2 where 
equated to EF values, MUS gave a negative value with an inter-day RSD of 
168.2%. This was an indication that the total peak area after 24 hrs was lower than 
the blank peak area calculated the previous day. The explanation might have been 
that the enhancing matrix effect had reduced due to loss of the interfering 
compound. The TRP EF value reduced from 21.57 to 15.31 giving an inter-day 
RSD value of 16.95%. These results are an indication that if the extraction were to 
be repeated after at least 24 hours of urine preservation, a new matrix-based 
calibration curve might be necessary using unspiked preserved urine in order to 
determine the extent of matrix changes. This procedure could not be done during 
this research as the amount of preserved urine was not enough to start new matrix-
based calibration curves. A new urine sample could not be collected as it could 
have had different properties and quantities of interfering compounds and results 
from such a sample would have been distorted. 
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When enrichment of the three analytes was tested again after 5 days, both MUS 
and TRP gave negative EF values while the EF value for TA had dropped to 13.14 
with the inter-day RSD rising to 25.9%. These results might have been an 
indication that urine from individuals suspected of hallucinogen consumption 
must be analysed as early as possible to avoid false negatives preferably on the 
day of urine sample collection. There might be need for new calibration curves if 
analysis is to be repeated after several hours of urine preservation. Alternatively, 
better preservation methods can be applied in order to minimize urine enzyme 
activity.   
 Comparative studies 5.9.3
Table 44 below gives a comparison of LODs and LOQs for extraction of MUS 
from urine samples using the current method and other methods that have been 
used before. The results show that better LOD values were obtained when the 
current HF-LPME approach was used. In Table 45, EF values of several 
compounds with polarity as high as the current study compounds that have been 
extracted from urine samples using the carrier-mediated HF-LPME approach. It 
was obvious that the EF values obtained from the HF-LPME for the extraction of 
muscimol and its two precursors were in the acceptable region.   
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Table 44 Comparison of LODs and LOQs, repeatability and reproducibility, and r² values for different methods that have used to 
extract MUS from urine samples. 
r² LOD (µg mL
-1
) Method Reference 
0.9868 0.021 HF-LPME with HPLC-UV Current 
0.9996 13 NMR-NOESY spectroscopy (Deja et al., 2014) 
0.9992 0.05 ng mL
-1 
 
Capillary electrophoresis coupled with 
electrospray tandem mass spectrometry 
(Ginterová et al., 2014) 
 
>0.99 1 
 
Cation exchanger  with derivatization 
(Dowex® 50W X8) with GC-MS 
(Stříbrný et al., 2012) 
0.9999 0.0025 
(in blood serum) 
Solid phase extraction with LC-MS-MS 
from blood serum 
(Hasegawa et al., 2013) 
Purpose was to quantify MUS and IBO from 
dog urine that had ingested mushrooms 
1Urine:3 mixture of methylene 
chloride /methanol with agitation 
(Rossmeisl et al., 2006) 
 
Purpose was to confirm presence of MUS in 
a patient’s urine. No validation was done 
Derivatization with N-methyl-N-
(trimethylsilyl) trifluoroacetamide 
(MSTFA) GC-MS 
(Garcia et al., 2015) 
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Table 45 EF values of polar compounds with X log P3 ≤ 1.6 that have been extracted from urine using carrier-mediated HF-LPME  
Compounds & 
X log P3 values 
 
SLM composition 
EF values in 
urine 
Urine 
dilution 
 
Instrument 
 
AP conc. 
 
Reference 
Muscimol, tryptophan, 
tryptamine (-1.4,  – 1.1, 1.6) 
20% (w/w) 
DEHPA in DHE 
4.1, 19.7, 24.1 
 
1.4 HPLC-UV 200 mM HCl Current 
Putrescine, cadaverine 
spermidine, spermine 
 (-0.9, -0.6,  -1,  -1.1) 
20% (w/w) 
DEHPA in DHE 
11.0, 13.6 
4.3, 13.1 
- HPLC-UV 200 mM HCl (Dziarkowska et 
al., 2008) 
Ephedrine  (0.9) 10%  (w/v)  TEHP  
in Toluene 
8 1:6 HPLC-UV 1mmol L
−1
 (Fotouhi et al., 
2011) 
Amphetamine, morphine, 
practolol (1.8,  0.8, 0.8) 
Sodium octanoate 
in octanol 
R (45–71%) 1:1 CE-UV 50 mM HCl (Ho et al., 2003) 
Morphine, codeine, thebaine, 
papaverine, noscapine, (0.8, 1.1, 
2.2, 3.9, 2.7) 
25 mM sodium 
octanoate in 
octanol 
R (17-45%) Undiluted HPLC-UV 50 mM HCl (Li et al., 2014) 
Salbutamol, terbutaline (0.3, 
0.9) 
20% Aliquat 336 in 
DHE 
52.9 
213.1 
(1:109) LC-MS 1M NaBr (Yamini et al., 
2006) 
Ephedrine (0.9) 15%  TEHP in 
Toluene 
35 1:6 HPLC-UV 100 mM HCl (Fotouhi et al., 
2011) 
* tris(2-ethylhexy)phosphate  TEHP 
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6 CONCLUSIONS AND RECOMMENDATIONS 
 Conclusions 6.1
An HPLC-UV system with a HILIC column was selected for the separation and 
quantification of analytes from urine samples. The mobile phase was acetonitrile-
buffer 90:10% (v/v) 10 mM formate. The results of this study showed that better 
separation in HILIC columns can be achieved if analyte diluents of relatively 
lower polarity are used to introduce analytes into a mobile phase of higher 
polarity. Tetrahydrofuran was recommended where acetonitrile is used as the 
organic component of the mobile phase. Extraction and enrichment of analytes 
from spiked urine samples was successfully achieved using a hollow fibre liquid 
phase microextraction.  The conditions for a simultaneous extraction of muscimol, 
tryptophan and tryptamine were a 20% (v/v) diluted urine sample at pH 4, an 
acceptor concentration of 200 mM HCl, 20% (w/w) DEHPA in DHE supported 
on the walls of a hollow fibre and stirring at 800 rpm for 60 mins. These universal 
factor values were biased towards maximizing the extraction of muscimol.  
The optimization procedure was meant to influence selectivity of the carrier-
mediated microextraction towards muscimol, tryptophan and tryptamine. 
However the complexity of urine resulted in peaks that could not be completely 
resolved from the analyte peaks. This was an indication of inability of the hollow 
fibre and the carrier molecule to completely discriminate analytes from the matrix. 
Thus the lack of method specificity or selectivity was compensated by calculating 
matrix effects which were in turn used to construct matrix-based calibration 
curves.  
Good coefficients of determination denoted by r
2
 were obtained from matrix-
based calibration curves and ranged from 0.9933 to 0.9986. Compared to other 
methods that have been applied for the extraction and quantification of muscimol 
from urine samples, the developed method offered better limits of detection of 
0.021 µg mL
-1 
for the extraction of muscimol. The enrichment factor values of 
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4.1, 19.7 and 24.1 for muscimol, tryptophan and tryptamine respectively were 
comparable with carrier-mediated HF-LPME enrichments of other compounds of 
similar polarity in the presence of matrix. Fair repeatability RSD values of the 
enrichment factors of 8.3%, 13.1% and 10.2% respectively were obtained.  
Dark yellow urine was used for matrix-based studies implying that the values 
reported in this research were the minimum possible for extraction of muscimol 
and its two precursors from a 20% (v/v) diluted urine solution. Also an acceptor 
of 200 mM HCl was considerably of lower acid concentration. A better H⁺ ion 
gradient and hence higher enrichment values would be obtained if a more 
concentrated HCl acceptor phase was used.  
The optimum factor values for individual extractions were different for each 
analyte. Because muscimol was the analyte of interest in this research, its 
optimum factor values were set as universal conditions for a simultaneous 
extraction. A compound desirability of 0.687 was considered acceptable 
considering that only one response output was used in determining the overall 
conditions of extraction.  
The results of this study are an indication that the developed HF-LPME method 
can be a viable alternative in the extraction and quantification of muscimol from 
urine samples. The method is environmentally friendly and has a further 
advantage of ensuring that sample extraction and clean-up are achieved in a single 
step with no need for a derivatization step. 
 Recommendations 6.2
Accuracy could have been addressed by applying the method on certified 
reference materials or comparing with another well-validated procedure. 
Hallucinogenic compounds are schedule 1 drugs and it was impossible to obtain 
their CRM in urine matrix. Neither could we obtain samples from individuals that 
had consumed hallucinogenic mushrooms. Administering MUS into volunteers 
could not be done as specialised monitoring procedures and appropriate therapy 
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protocol would have been required to address potential risks associated with 
hallucinating (Garcia et al., 2015; Johnson et al., 2008).  
Peak identification was achieved by comparison of elution times of analytes when 
these analytes were spiked into the acceptor phase that had been diluted 
accordingly with specific diluents for injection into the HPLC. An HPLC-MS 
detector could have been a better instrument for analyte identification. 
System suitability was limited to an HPLC-UV approach. An MS detector could 
have been used in order to identify the analytes and interfering compounds. A 
better H⁺ ion gradient and hence higher EF values are predicted if a more 
concentrated HCl acceptor phase was used.  
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APPENDIX 
Table A 1  Randomized design table showing 32 experimental runs. The two 
levels of each of the six factors are sign coded 
Run A B C D E F 
1 - + - - - + 
2 + - - - + - 
3 - - + + - - 
4 + + + + + + 
5 - + - + + + 
6 + + - - - - 
7 - - + + + + 
8 - - + - + - 
9 + - - + + + 
10 + - + - + + 
11 - - - - - - 
12 + - + + + - 
13 - - - + - + 
14 - - + - - + 
15 + - + + - + 
16 - + - - + - 
17 - + + + + - 
18 + - - + - - 
19 + - - - - + 
20 + + - - + + 
21 - - - + + - 
22 + + - + - + 
23 + + - + + - 
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24 - + + - - - 
25 - + + + - + 
26 - + - + - - 
27 + - + - - - 
28 - - - - + + 
29 + + + + - - 
30 - + + - + + 
31 + + + - - + 
32 + + + - + - 
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Table A 2   Randomized central composite design for the essential factors for 
MUS at  
Run A B C D 
1 -2 0 0 0 
2 0 2 0 0 
3 0 0 0 -2 
4 0 -2 0 0 
5 0 0 -2 0 
6 0 0 2 0 
7 0 0 0 2 
8 0 0 0 0 
9 0 0 0 0 
10 2 0 0 0 
11 -1 1 -1 1 
12 0 0 0 0 
13 0 0 0 0 
14 1 -1 -1 -1 
15 1 -1 1 -1 
16 -1 1 1 1 
17 1 1 1 -1 
18 -1 -1 1 -1 
19 -1 -1 1 1 
20 1 1 -1 1 
21 1 -1 1 1 
22 -1 -1 -1 1 
23 0 0 0 0 
24 -1 -1 -1 -1 
25 1 -1 -1 1 
26 1 1 1 1 
27 -1 1 -1 -1 
28 1 1 -1 -1 
29 0 0 0 0 
30 -1 1 1 -1 
  
2
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Table A 3   Randomized coded CCD for the essential factors for MUS at  
Run A B C D 
1 0 0 0 2 
2 2 0 0 0 
3 0 0 -2 0 
4 0 0 0 -2 
5 0 0 0 0 
6 0 -2 0 0 
7 -2 0 0 0 
8 0 0 2 0 
9 0 0 0 0 
10 0 2 0 0 
11 -1 1 -1 -1 
12 1 1 -1 -1 
13 1 1 1 1 
14 0 0 0 0 
15 -1 1 1 1 
16 1 1 1 1 
17 1 1 -1 1 
18 -1 1 -1 1 
19 -1 -1 1 -1 
20 -1 -1 1 1 
21 -1 1 1 -1 
22 -1 -1 -1 -1 
23 1 1 1 -1 
24 0 0 0 0 
25 1 -1 -1 -1 
26 0 0 0 0 
27 1 -1 1 1 
28 -1 -1 -1 1 
29 1 -1 1 -1 
30 0 0 0 0 
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Figure A 1   Calibration curve for MUS (n = 3, SD)  
   
 
Figure A 2   Calibration curve for PSI (n = 3, SD) 
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Figure A 3   Calibration curve for TRP (n = 3, SD) 
 
   
 Figure A 4   Calibration curve for TA (n= 3, SD) 
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Table A 4      Peak areas for TA when 32 runs were investigated. 
Run 
Order 
DP 
pH 
AP HCl 
conc 
SLM 
compo 
Extraction 
time 
Stirring 
rate 
 
%NaCl 
 
Peak Area 1 
 
Peak Area 2 
 
Peak Area 3 
 
Average 
1 3 100 5 10 600 0.01 59.866 53.866 56.296 56.676 
2 7 10 5 10 800 0.001 31.709 33.705 29.847 31.754 
3 3 10 20 30 600 0.001 71.662 74.426 74.092 73.393 
4 7 100 20 30 800 0.01 441.497 456.479 449.002 448.993 
5 3 100 5 30 800 0.01 61.521 61.057 62.157 61.578 
6 7 100 5 10 600 0.001 16.204 18.820 19.479 18.168 
7 3 10 20 30 800 0.01 71.563 73.190 71.784 72.179 
8 3 10 20 10 800 0.001 80.475 80.725 80.578 80.593 
9 7 10 5 30 800 0.01 69.610 68.289 68.713 68.871 
10 7 10 20 10 800 0.01 110.686 111.577 110.830 111.031 
11 3 10 5 10 600 0.001 33.437 31.668 31.937 32.347 
12 7 10 20 30 800 0.001 96.446 95.746 95.631 95.941 
13 3 10 5 30 600 0.01 34.644 35.736 35.049 35.143 
14 3 10 20 10 600 0.01 76.848 76.954 76.599 76.800 
15 7 10 20 30 600 0.01 123.207 122.530 123.637 123.125 
16 3 100 5 10 800 0.001 55.323 59.056 55.874 56.751 
17 3 100 20 30 800 0.001 289.361 290.385 291.201 290.316 
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18 7 10 5 30 600 0.001 27.766 26.030 26.893 26.896 
19 7 10 5 10 600 0.01 47.753 39.743 39.649 42.382 
20 7 100 5 10 800 0.01 67.659 71.480 69.346 69.495 
21 3 10 5 30 800 0.001 47.842 48.286 47.978 48.035 
22 7 100 5 30 600 0.01 72.697 71.890 73.295 72.627 
23 7 100 5 30 800 0.001 61.973 64.573 64.149 63.565 
24 3 100 20 10 600 0.001 170.143 168.789 169.310 169.414 
25 3 100 20 30 600 0.01 333.275 329.136 327.376 329.929 
26 3 100 5 30 600 0.001 34.062 29.230 33.027 32.106 
27 7 10 20 10 600 0.001 87.369 91.882 91.573 90.275 
28 3 10 5 10 800 0.01 34.030 32.233 34.536 33.600 
29 7 100 20 30 600 0.001 479.605 456.772 467.892 468.090 
30 3 100 20 10 800 0.01 165.085 164.553 170.857 166.832 
31 7 100 20 10 600 0.01 230.043 221.228 227.793 226.355 
32 7 100 20 10 800 0.001 294.154 300.395 299.356 297.968 
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Table A 5    Summary of variances of 32 runs done at 3 repeat experiments each 
Run Count 
Sum of 
peak areas 
Average 
peak area Variance 
1 3 170.028 56.676 9.108 
2 3 95.261 31.754 3.723 
3 3 220.18 73.393 2.276 
4 3 1346.978 448.993 56.115 
5 3 184.735 61.578 0.305 
6 3 54.503 18.168 3.001 
7 3 216.537 72.179 0.779 
8 3 241.778 80.593 0.016 
9 3 206.612 68.871 0.455 
10 3 333.093 111.031 0.229 
11 3 97.042 32.347 0.909 
12 3 287.823 95.941 0.195 
13 3 105.429 35.143 0.305 
14 3 230.401 76.800 0.033 
15 3 369.374 123.125 0.311 
16 3 170.253 56.751 4.061 
17 3 870.947 290.316 0.850 
18 3 80.689 26.896 0.753 
19 3 127.145 42.382 21.641 
20 3 208.485 69.495 3.667 
21 3 144.106 48.035 0.052 
22 3 217.882 72.627 0.497 
23 3 190.695 63.565 1.946 
24 3 508.242 169.414 0.466 
25 3 989.787 329.929 9.171 
26 3 96.319 32.106 6.473 
27 3 270.824 90.275 6.356 
28 3 100.799 33.600 1.465 
29 3 1404.269 468.090 130.366 
30 3 500.495 166.832 12.223 
31 3 679.064 226.355 20.978 
32 3 893.905 297.968 11.182 
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Table A 6   Enrichment factor values for TA when 32 runs were investigated. 
Run 
Order 
DP 
pH 
AP HCl 
 conc 
SLM 
compo 
Extraction 
time 
Stirring 
rate %NaCl 
 
EF values 
1 3 100 5 10 600  15.5 
2 7 10 5 10 800 0.01 28.9 
3 3 10 20 30 600 0.001 32.1 
4 7 100 20 30 800 0.001 204.2 
5 3 100 5 30 800 0.01 27.9 
6 7 100 5 10 600 0.01 8.5 
7 3 10 20 30 800 0.001 36.8 
8 3 10 20 10 800 0.01 55.3 
9 7 10 5 30 800 0.001 36.7 
10 7 10 20 10 800 0.01 61.9 
11 3 10 5 10 600 0.01 19.8 
12 7 10 20 30 800 0.001 51.1 
13 3 10 5 30 600 0.001 15.3 
14 3 10 20 10 600 0.01 36.2 
15 7 10 20 30 600 0.01 60.4 
16 3 100 5 10 800 0.01 26.7 
17 3 100 20 30 800 0.001 148.4 
18 7 10 5 30 600 0.001 18.4 
19 7 10 5 10 600 0.001 26.0 
20 7 100 5 10 800 0.01 31.5 
21 3 10 5 30 800 0.01 24.5 
22 7 100 5 30 600 0.001 33.0 
23 7 100 5 30 800 0.01 29.9 
24 3 100 20 10 600 0.001 74.3 
25 3 100 20 30 600 0.001 226.8 
26 3 100 5 30 600 0.01 15.1 
27 7 10 20 10 600 0.001 46.1 
28 3 10 5 10 800 0.001 17.1 
29 7 100 20 30 600 0.01 221.0 
30 3 100 20 10 800 0.001 102.7 
31 7 100 20 10 600 0.01 106.8 
32 7 100 20 10 800 0.01 166.3 
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Table A 7   Peak area values for MUS when 32 runs were investigated. 
Run 
Order 
DP 
pH 
AP HCl 
conc 
SLM 
compo 
Extraction 
time 
Stirring 
rate %NaCl 
 
Peak Area 1 
 
Peak Area 2 
 
Peak Area 3 
 
Average 
1 3 100 5 10 600 0.01 7.915 7.088 7.313 7.439 
2 7 10 5 10 800 0.001 17.957 18.559 19.561 18.692 
3 3 10 20 30 600 0.001 16.242 16.267 16.127 16.212 
4 7 100 20 30 800 0.01 4.024 4.901 5.069 4.665 
5 3 100 5 30 800 0.01 10.393 11.246 12.476 11.372 
6 7 100 5 10 600 0.001 4.776 4.776 4.698 4.750 
7 3 10 20 30 800 0.01 18.340 20.541 19.568 19.483 
8 3 10 20 10 800 0.001 8.476 8.956 9.599 9.010 
9 7 10 5 30 800 0.01 5.638 5.176 5.712 5.509 
10 7 10 20 10 800 0.01 8.517 9.927 10.859 9.768 
11 3 10 5 10 600 0.001 3.690 4.224 4.168 4.027 
12 7 10 20 30 800 0.001 11.729 12.089 9.384 11.067 
13 3 10 5 30 600 0.01 6.812 7.075 7.106 6.998 
14 3 10 20 10 600 0.01 4.527 3.690 4.256 4.158 
15 7 10 20 30 600 0.01 6.490 7.961 6.490 6.980 
16 3 100 5 10 800 0.001 11.924 12.452 10.598 11.658 
17 3 100 20 30 800 0.001 12.818 12.890 12.839 12.849 
18 7 10 5 30 600 0.001 5.971 11.338 9.578 8.962 
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19 7 10 5 10 600 0.01 3.501 2.082 2.130 2.571 
20 7 100 5 10 800 0.01 9.991 10.672 9.869 10.177 
21 3 10 5 30 800 0.001 27.352 27.900 27.984 27.745 
22 7 100 5 30 600 0.01 5.664 3.398 1.836 3.633 
23 7 100 5 30 800 0.001 13.290 13.154 13.199 13.214 
24 3 100 20 10 600 0.001 16.573 17.942 15.783 16.766 
25 3 100 20 30 600 0.01 17.018 21.644 - 19.331 
26 3 100 5 30 600 0.001 14.584 33.224 - 23.904 
27 7 10 20 10 600 0.001 12.454 13.024 13.107 12.862 
28 3 10 5 10 800 0.01 4.179 4.482 4.350 4.337 
29 7 100 20 30 600 0.001 10.224 11.364 9.978 10.522 
30 3 100 20 10 800 0.01 28.867 28.063 - 28.465 
31 7 100 20 10 600 0.01 19.452 18.724 - 19.088 
32 7 100 20 10 800 0.001 10.182 8.702 10.258 9.714 
 
 
 
156 
 
Table A 8    Summary of variances of 32 runs done at 3 repeat experiments each 
for MUS 
Run Count 
Sum of 
peak areas 
Average 
peak area Variance 
1 3 56.077 18.692 0.657 
2 3 22.316 7.439 0.183 
3 3 48.636 16.212 0.006 
4 3 13.994 4.665 0.315 
5 3 34.115 11.372 1.097 
6 3 14.250 4.750 0.002 
7 3 58.449 19.483 1.217 
8 3 27.031 9.010 0.317 
9 3 16.526 5.509 0.084 
10 3 29.303 9.768 1.390 
11 3 12.082 4.027 0.086 
12 3 33.202 11.067 2.158 
13 3 20.993 6.998 0.026 
14 3 12.473 4.158 0.182 
15 3 20.941 6.980 0.721 
16 3 34.974 11.658 0.912 
17 3 38.547 12.849 0.001 
18 3 26.887 8.962 7.485 
19 3 7.713 2.571 0.649 
20 3 30.532 10.177 0.187 
21 3 83.236 27.745 0.118 
22 3 10.898 3.633 3.705 
23 3 39.643 13.214 0.005 
24 3 50.298 16.766 1.193 
25 3 38.662 19.331 10.700 
26 3 47.808 23.904 173.725 
27 3 38.585 12.862 0.126 
28 3 13.011 4.337 0.023 
29 3 31.566 10.522 0.547 
30 3 56.930 28.465 0.323 
31 3 29.142 9.714 0.265 
32 3 38.176 19.088 0.770 
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Table A 9   Enrichment factor values for MUS when 32 runs were investigated. 
Run 
Order DP pH 
AP HCl 
conc 
SLM 
compo 
Extraction 
time 
Stirring 
rate 
 
%NaCl 
 
EF values 
1 3 100 5 10 600 0.01 9.2 
2 7 10 5 10 800 0.001 3.7 
3 3 10 20 30 600 0.001 8.0 
4 7 100 20 30 800 0.01 2.3 
5 3 100 5 30 800 0.01 5.6 
6 7 100 5 10 600 0.001 2.3 
7 3 10 20 30 800 0.01 9.6 
8 3 10 20 10 800 0.001 4.4 
9 7 10 5 30 800 0.01 2.7 
10 7 10 20 10 800 0.01 4.8 
11 3 10 5 10 600 0.001 2.0 
12 7 10 20 30 800 0.001 5.5 
13 3 10 5 30 600 0.01 3.4 
14 3 10 20 10 600 0.01 2.0 
15 7 10 20 30 600 0.01 3.4 
16 3 100 5 10 800 0.001 5.8 
17 3 100 20 30 800 0.001 6.3 
18 7 10 5 30 600 0.001 4.4 
19 7 10 5 10 600 0.01 1.2 
20 7 100 5 10 800 0.01 5.0 
21 3 10 5 30 800 0.001 13.7 
22 7 100 5 30 600 0.01 1.8 
23 7 100 5 30 800 0.001 6.5 
24 3 100 20 10 600 0.001 8.3 
25 3 100 20 30 600 0.01 9.6 
26 3 100 5 30 600 0.001 11.8 
27 7 10 20 10 600 0.001 6.4 
28 3 10 5 10 800 0.01 2.1 
29 7 100 20 30 600 0.001 5.2 
30 3 100 20 10 800 0.01 14.1 
31 7 100 20 10 600 0.01 4.8 
32 7 100 20 10 800 0.001 9.4 
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Figure A 5   Matrix-based calibration curve for the extraction of MUS from 
diluted urine samples and spiked up to a concentration of 10 µgLˉ¹. The acceptor 
phase had been diluted 6 fold (n = 3, SD). 
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